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Background: Around one-third of pregnant women suffer from moderate to severe nausea and
vomiting, causing physical and emotional distress and reducing their quality of life. There is no cure
for nausea and vomiting in pregnancy. Management focuses on relieving symptoms and preventing
morbidity, and often requires antiemetic therapy. National guidelines make recommendations about
first-, second- and third-line antiemetic therapies, although care varies in different hospitals and
women report feeling unsupported, dissatisfied and depressed.
Objectives: To determine whether or not, in addition to intravenous rehydration, ondansetron
compared with no ondansetron and metoclopramide compared with no metoclopramide reduced the
rate of treatment failure up to 10 days after drug initiation; improved symptom severity at 2, 5 and
10 days after drug initiation; improved quality of life at 10 days after drug initiation; and had an
acceptable side effect and safety profile. To estimate the incremental cost per treatment failure
avoided and the net monetary benefits from the perspectives of the NHS and women.
Design: This was a multicentre, double-dummy, randomised, double-blinded, dummy-controlled 2 × 2
factorial trial (with an internal pilot phase), with qualitative and health economic evaluations.
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Participants: Thirty-three patients (who were < 17 weeks pregnant and who attended hospital with
nausea and vomiting after little or no improvement with first-line antiemetic medication) who attended
12 secondary care NHS trusts in England, 22 health-care professionals and 21 women participated
in the qualitative evaluation.
Interventions: Participants were randomly allocated to one of four treatment groups (1 : 1 : 1: 1 ratio):
(1) metoclopramide and dummy ondansetron; (2) ondansetron and dummy metoclopramide;
(3) metoclopramide and ondansetron; or (4) double dummy. Trial medication was initially given
intravenously and then continued orally once women were able to tolerate oral fluids for a maximum
of 10 days of treatment.
Main outcome measures: The primary end point was the number of participants who experienced
treatment failure, which was defined as the need for further treatment because symptoms had
worsened between 12 hours and 10 days post treatment. The main economic outcomes were
incremental cost per additional successful treatment and incremental net benefit.
Results: Of the 592 patients screened, 122 were considered eligible and 33 were recruited into the
internal pilot (metoclopramide and dummy ondansetron, n = 8; ondansetron and dummy metoclopramide,
n = 8; metoclopramide and ondansetron, n = 8; double dummy, n = 9). Owing to slow recruitment, the trial
did not progress beyond the pilot. Fifteen out of 30 evaluable participants experienced treatment failure.
No statistical analyses were performed. The main reason for ineligibility was prior treatment with trial
drugs, reflecting an unpredicted change in prescribing practice at several points along the care pathway.
The qualitative evaluation identified the requirements of the study protocol, in relation to guidelines on
anti-sickness drugs, and the diversity of pathways to care as key hurdles to recruitment while the role of
research staff was a key enabler. No important adverse events or side effects were reported.
Limitations: The pilot trial failed to achieve the recruitment target owing to unforeseen changes in the
provision of care.
Conclusions: The trial was unable to provide evidence to support clinician decisions about the best
choice of second-line antiemetic for nausea and vomiting in pregnancy.
Trial registration: Current Controlled Trials ISRCTN16924692 and EudraCT 2017-001651-31.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 63. See the NIHR Journals Library website for further project information.
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Plain English summary
Nausea and vomiting in pregnancy cause physical and emotional distress, and up to 30% of affectedwomen require medical treatment. Guidelines on the use of anti-sickness drugs exist, but
evidence is limited about which drugs work the best.
The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare
the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide
hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron
(ondansetron hydrochloride dehydrate,Wockhardt UK Ltd,Wrexham, UK; IV Hameln Pharma plus GmbH,
Hameln)] for the treatment of nausea and vomiting in pregnancy.Women who were < 17 weeks pregnant
with severe nausea and vomiting who attended hospital because their first anti-sickness drug had failed
to improve their symptoms were asked to take part in the trial. Participants received fluids and, with
consent, were randomly allocated to one of four groups: (1) metoclopramide and dummy ondansetron,
(2) ondansetron and dummy metoclopramide, (3) metoclopramide and ondansetron or (4) double dummy.
Trial drugs were administered into a vein and then by tablet for 10 days. On advice from sufferers, the
trial focused on treatment failure, but other outcomes, including drug side effects, costs and pregnancy
outcome, were collected.
The trial was unable to recruit enough women and, therefore, did not progress. Nearly 600 women at
11 hospitals were screened, of whom 122 (21%) were eligible and 33 were recruited. The main reason
for ineligibility (68%) was prior use of trial drug (mostly ondansetron). Overall, 15 out of 30 evaluable
women experienced treatment failure.
Interviews with 21 women who were approached about the trial and 22 research staff identified
complex hurdles to and enablers of recruitment. The main hurdles were the requirements of the study
protocol in relation to guidelines on anti-sickness drugs and the diversity of pathways to care. The role
of research staff was a key enabler.
The trial was too small to draw useful conclusions and it highlights the challenges of conducting
complex studies on sick pregnant women. Subsequent concerns about the safety of ondansetron
highlight the need for further studies to help inform women and the NHS about the best care for
nausea and vomiting in pregnancy.
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Nausea and vomiting in pregnancy affects a high percentage of women, with symptoms usually starting
at 6–8 weeks’ gestation. Symptoms can be mild, but one-third of sufferers experience more severe
symptoms. The most severe form (hyperemesis gravidarum) is characterised by vomiting, dehydration,
ketonuria and weight loss. Severe nausea and vomiting in pregnancy can result in prolonged hospitalisation,
multiple treatments and, where interventions fail, termination of pregnancy. It is also associated with
emotional and psychological distress and has a profound impact on quality of life.
The cause of nausea and vomiting remains unclear and there is no cure. Management focuses on
relieving symptoms and preventing morbidity. Women with mild symptoms are often able to self-manage
the condition, but those with moderate or severe disease often require clinician-initiated interventions
in the form of intravenous fluids and antiemetic drugs, primarily antihistamines (e.g. cyclizine), dopamine
antagonists (e.g. metoclopramide) and 5-hydroxytryptamine 3 antagonists (e.g. ondansetron).
Nausea and vomiting in pregnancy incur substantial costs to sufferers and to the NHS. Assessment
of the condition often lacks consistency, and antiemetic treatment varies across NHS trusts. To address
this, in June 2016 the Royal College of Obstetricians and Gynaecologists published guidelines on the
management of nausea and vomiting in pregnancy [Royal College of Obstetricians and Gynaecologists. The
Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum. 2016. URL: www.rcog.org.uk/
globalassets/documents/guidelines/green-top-guidelines/gtg69-hyperemesis.pdf (accessed 9 July 2020)].
An evidence synthesis suggested that some treatments were better than the dummy for mild symptoms,
but there was limited evidence on the clinical effectiveness and cost-effectiveness of treatments for more
severe vomiting. Although limited data suggested that metoclopramide and promethazine alleviated
moderate symptoms, evidence for ondansetron was at high or unclear risk of bias. The evidence
synthesis identified the need for a randomised controlled trial, including economic evaluation, to
determine which second-line hospital-prescribed antiemetic therapy, in addition to intravenous
rehydration, should be adopted as mainstream provision in the UK NHS.
Objectives
The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to determine
which second-line hospital-prescribed therapy [metoclopramide (metoclopramide hydrochloride,
Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron
hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)],
in addition to intravenous rehydration, should be adopted as mainstream second–line treatment of
severe nausea and vomiting in pregnancy by the NHS when first-line treatment has failed. To achieve
these aims, the following objectives were set.
Primary objective
To determine whether or not, in addition to intravenous rehydration, ondansetron compared with no
ondansetron and metoclopramide compared with no metoclopramide reduced the rate of treatment
failure up to 10 days after initiation.
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Secondary objectives
To determine whether or not, in addition to intravenous rehydration, ondansetron compared with no
ondansetron and metoclopramide compared with no metoclopramide:
l improved symptom severity at 2, 5 and 10 days after intervention initiation
l improved quality of life at 10 days after intervention initiation
l had an acceptable side effect and safety profile.
In addition, we aimed to estimate the incremental cost per treatment failure avoided and the net
monetary benefits from the perspective of the NHS and women and their families.
Internal pilot and qualitative trial objectives
The aim of the internal pilot phase was to assess the feasibility of recruitment and the retention of
participants recruited into the trial. The aim of the qualitative component of the pilot trial was improve
our understanding of why women did or did not consent to participation in the trial.
Methods
The EMPOWER trial was a multicentre, double-dummy, randomised, double-blinded, dummy-controlled
2 × 2 factorial trial with an internal pilot phase. Women attending hospital with severe nausea and
vomiting in pregnancy who had experienced little or no improvement after taking first-line antiemetic
medication were invited to participate. The trial was conducted in a secondary care setting (i.e. within
gynaecology/early pregnancy units, maternity assessment units and/or accident and emergency
departments, depending on local care pathways) in 12 NHS trusts in England.
Inclusion criteria
l Pregnant women suffering from severe nausea and vomiting in pregnancy.
l Gestation of < 17 weeks.
l Had previously taken first-line antiemetic treatment (cyclizine, chlorpromazine, promethazine,
prochlorperazine or doxylamine/pyridoxine) as prescribed, that is over a minimum of 24 hours with
no sustained improvement in symptoms.
l Age ≥ 18 years.
l Able to give informed consent.
l Able to read/understand written English.
Exclusion criteria
l Allergy/hypersensitivity to any of the study drugs.
l Received either ondansetron or metoclopramide intravenously.
l Received either ondansetron or metoclopramide orally for > 72 hours (with or without
intravenous rehydration).
l Pre-existing diagnosis of a medical condition: type 1 or 2 diabetes mellitus, chronic kidney disease
stages 3–5, Graves’ disease, significant cardiac disease (including long QT syndrome),
phaeochromocytoma or epilepsy (or other seizure disorder).
l Moderate renal impairment (known chronic kidney disease grades 3b/4/5 or serum creatinine levels
> 100 µmol/l in pregnancy).
l Known pre-existing diagnosis of severe liver impairment (e.g. alanine transferase or aspartate
transaminase levels > 2.5 times the upper limit of normal pregnancy levels).
l Severe diarrhoea [definition: > 10 loose, watery stools in 1 day (24 hours)].
l Hypokalaemia.
l Known pre-existing diagnosis of hypomagnesaemia.
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l Vomiting caused by another underlying condition/infection.
l Concomitant use of apomorphine or serotonergic drugs (e.g. selective serotonin reuptake inhibitors,
monoamine oxidase inhibitors and lithium).
l Confirmed diagnosis of severe lactose intolerance (e.g. patients with rare hereditary problems of
galactose intolerance, Lapp lactase deficiency or glucose–galactose malabsorption).
Randomisation was carried out centrally using a secure web-based system. Participants were randomised
on a 1 : 1 : 1 : 1 basis using a block-stratified method (stratified by site only) to receive either:
l metoclopramide (10 mg three times daily) and dummy (three times daily)
l ondansetron (4 mg three times daily) and dummy (three times daily)
l metoclopramide (10 mg three times daily) and ondansetron (4 mg three times daily)
l double dummy (three times daily).
Drugs were initially given intravenously then orally for a total of 10 days.
Measurements of outcomes
Primary outcome measure
The primary outcome measure was the number of participants experiencing treatment failure, defined
as the need for further (third-line) antiemetic treatment because the participant’s symptoms had not
improved between 12 hours and 10 days post first dose of study drugs.
Secondary outcome measures
The secondary outcome measures were participant-reported measures of symptom severity and
quality of life at 2, 5 and 10 days after intervention initiation that were assessed via completion of
the following questionnaires: Pregnancy Unique Quantification of Emesis; Visual Analogue Scale for
Nausea; Nausea and Vomiting during Pregnancy Quality of Life; Edinburgh Postnatal Depression Scale;
six-item State–Trait Anxiety Inventory; and Maternal Social Support Scale. All questionnaires, except
the visual analogue scale for nausea, were completed at baseline. The Nausea and Vomiting during
Pregnancy Quality of Life, Edinburgh Postnatal Depression Scale and State–Trait Anxiety Inventory
were also collected at day 10. The Pregnancy Unique Quantification of Emesis and visual analogue
scale for nausea were also collected at days 2, 5 and 10.
The side effects and safety profile of the trial medication were assessed by asking participants during
follow-up telephone calls that were conducted 2, 5 and 10 days after commencing trial medication
whether or not they had experienced any adverse events. A grading system was used whereby patients
were asked what symptoms they were experiencing at baseline (prior to commencing trial medication)
and, subsequently, only new or worsening symptoms needed to be reported during the follow-up
telephone calls.
Internal pilot
The main outcomes of the internal pilot phase were the recruitment and retention rates of participants
in the trial to day 10. To progress from the pilot trial to the main trial, 59 participants needed to be
recruited within 6 months, with ≥ 40 participants retained to day 10.
Sample size
As per the 2 × 2 factorial design, the trial was designed to have two main comparisons:
1. metoclopramide compared with no metoclopramide
2. ondansetron compared with no ondansetron.
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We assumed an antiemetic failure rate of 10% based on prior ondansetron studies and our external
pilot trial of midwife-led outpatient care. With 266 participants in each comparison (i.e. 133 in each of
the four treatment combinations; 532 in total) and assuming no interaction between the two active
treatments, it was estimated that we would have 90% power to detect an increase in failure rate
from 10% in either antiemetic group to 20% in either dummy group (based on a two-sided test at the
5% level). Given that the primary outcome was treatment failure, we anticipated obtaining outcome
data from ≥ 90% of participants. To account for a 10% drop-out rate, we planned to recruit 600
patients (150 in each randomised group).
Statistical methods
Given that the trial did not progress past the internal pilot phase, none of the planned statistical
analyses was performed. Outcome data have been summarised descriptively by randomised treatment
group. Had the trial progressed to the main stage, analyses would have been based on a comparison of:
l active metoclopramide (with either active or dummy ondansetron) and dummy metoclopramide
(with either active or dummy ondansetron)
l active ondansetron (with either active or dummy metoclopramide) and dummy ondansetron
(with either active or dummy metoclopramide).
Health economic analysis
To estimate the incremental cost per treatment failure avoided and the net monetary benefits from
the perspective of the NHS and women, health utilisation and contingent valuation questionnaires
were completed by participants at day 10. Information was collected on accident and emergency
attendance, receipt of primary care and other NHS/Personal Social Services care services, medication
and the purchase of private health care or personal care. Participants were also asked to express their
willingness to pay to improve symptom severity for a 10-week period.
Qualitative study
The sample comprised women who accepted or declined trial participation and research staff.
Interviews were completed by e-mail or telephone using a structured topic guide. All transcripts were
checked for accuracy, anonymised and entered on NVivo 12 (QSR International, Warrington, UK) for
indexing and retrieval. Data were analysed using a generative thematic approach.
Results
Between April 2018 and August 2019, 592 patients were screened, with 122 considered eligible.
Thirty-three patients were recruited, with 29 retained to day 10. The main reason for ineligibility
was prior treatment with trial medication(s) in the current pregnancy (n = 320; 68%). This remained
the case, despite broadening the eligibility criteria to allow patients who had received only suboptimal
treatment to be included (orally for < 72 hours). Owing to slower than anticipated recruitment, the
trial did not progress from the internal pilot stage. Overall, 30 participants were evaluable for the
primary outcome of treatment failure (metoclopramide and dummy, n = 7; ondansetron and dummy,
n = 8; metoclopramide and ondansetron, n = 8; double dummy n = 7). Of those evaluable, 15 participants
(50%) reported treatment failure [metoclopramide and dummy, n = 4 (57%); ondansetron and dummy,
n = 2 (25%); metoclopramide and ondansetron, n = 4 (50%); double dummy, n = 5 (71%)].
Health economics results
Overall, 48% of participants did not complete any part of the Healthcare Utilisation and Contingent
Valuation questionnaires. Thirteen participants (39%) provided the maximum amount that they would
be willing to pay to improve symptom severity for a 10-week period, with a mean value across all
groups of £674 (minimum £20.00, maximum £2000).
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Qualitative results
Twenty-one women and 22 research staff were interviewed. Altogether, 72 codes were generated,
of which 36 nodes related to patient interviews and 36 to research staff. The hurdles to and enablers
of recruitment mapped to three themes: (1) requirements of the EMPOWER trial in the context of
the Royal College of Obstetricians and Gynaecologists guidelines, (2) the presentation of women to
maternity services and (3) research staff roles.
Conclusions
Owing to the small sample size, it was not possible to draw meaningful conclusions from the main trial
outcomes or the health economic outcomes. Overall, the treatment failure rate observed (50%) was
higher than predicted in the sample size calculation at the design stage (10–20%). A higher proportion
of women than anticipated were ineligible for the trial; the main reason was prior prescription of trial
medication(s). This reflected a change in prescribing practice, often inconsistent with national antiemetic
guidelines, with greater use of second-line drugs, particularly ondansetron. The qualitative study
identified that the hurdles to and enablers of recruitment were both trial specific and site specific.
Recommendations for future research
Further research is needed on the clinical effectiveness and cost-effectiveness of treatment strategies
in women with nausea and vomiting in pregnancy who fail to achieve symptom improvement with
first-line antiemetic drugs. Further research is also required to understand the barriers to recruitment
of complex randomised controlled trials involving pregnant women.
Trial registration
This trial is registered as ISRCTN16924692 and EudraCT 2017-001651-31.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 63.
See the NIHR Journals Library website for further project information.
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Nausea and vomiting in pregnancy (NVP) affects up to 85% of women in the first half of pregnancy.1
Symptoms usually start at 6–8 weeks’ gestation, peak by 9 weeks’ gestation and, for many women, subside
by 20 weeks’ gestation.2 Symptoms are often mild, but 30% of sufferers experience more severe symptoms
that require medical intervention.2 The most severe form, hyperemesis gravidarum (HG), affects around 1%
of women and is characterised by intractable vomiting, dehydration, ketonuria and weight loss.1,3 HG can
result in prolonged hospitalisation, multiple treatments and, where interventions fail, termination of
pregnancy (TOP). NVP is associated with emotional and psychological distress and has a profound impact
on quality of life (QoL), affecting all aspects of a woman’s life.4 Women often feel unsupported; suffer
higher rates of depression, anxiety and stress;5 and feel dissatisfied with care.6 Women with HG are also
more likely to deliver preterm and to have infants small for their gestational age, although there is no
association with congenital anomalies or perinatal death.7
The aetiology remains unclear, and there is no cure for NVP: treatment focuses on relieving symptoms
and preventing morbidity. Many women with mild symptoms are able to self-manage the condition
using lifestyle modifications. Some also access other patient-initiated interventions (e.g. ginger and
vitamins). Many women with moderate or severe disease require clinician-initiated interventions in the
form of intravenous (i.v.) fluids and antiemetic drugs, primarily antihistamines (e.g. cyclizine), dopamine
antagonists (e.g. metoclopramide) and 5-hydroxytryptamine3 (5-HT3) antagonists (e.g. ondansetron).
Rationale
Nausea and vomiting in pregnancy incur substantial costs to sufferers (through the purchase of therapies,
extra living or child-care costs or lost earnings8) and to the NHS. NVP resulted in > 30,000 admissions
to hospital in England in 2013–14, with one-third for HG with metabolic disturbance.9 Based on data
collected between 2013 and 2016, the annual cost of NVP to the UK NHS was estimated at nearly £26M;
however, owing to perceived underestimation of costs, the authors suggested that the cost could be
as high as £62M.8 Antiemetics are the most commonly dispensed drugs in early pregnancy, with over
10% of pregnant women in the US Medicaid Program prescribed promethazine or metoclopramide.10
The assessment of the severity of NVP often lacks consistency, and the management varies substantially.
This, combined with inappropriate treatment for presenting symptom severity, can leave women feeling
unsupported, dissatisfied with care and experiencing negative interpersonal interactions with health-
care providers.6,11 This, in part, may be because of a previous lack of evidence-based guidelines to
inform effective treatments in clinical practice. To address this, in June 2016 the Royal College of
Obstetricians and Gynaecologists (RCOG) published guidelines on the management of NVP and HG.12
Recommendations included the use of cyclizine, prochlorperazine, promethazine and chlorpromazine
as first-line antiemetic therapies, and metoclopramide, domperidone and ondansetron as second-line
antiemetic therapies.
In 2016, we reported a Health Technology Assessment (HTA)-funded evidence synthesis of the clinical
effectiveness and cost-effectiveness of treatments for NVP or HG.13 Seventy-three studies were
identified and the results were narratively synthesised because the planned meta-analysis was not
possible owing to the heterogeneity in the assessment of symptom severity, interventions, methods
and outcomes, as well as incomplete reporting. There was variation in both the quality of the studies
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and the quality of reporting. For almost half of all randomised controlled trials (RCTs) identified, there
was insufficient detail provided to permit clear judgement of the risk of bias in a range of key areas.
There was also insufficient evidence to form a judgement on cost-effectiveness. Two Cochrane reviews
were reported around the same time: Matthews et al.14 reviewed interventions for nausea and vomiting
in early pregnancy (41 trials) and Boelig et al.15 reviewed interventions for treating HG (25 trials).
Both reviews also highlighted that the evidence surrounding the effectiveness of treatments was both
sparse and of poor quality. All three reviews13–15 concluded that, although there was some evidence
that some treatments were better than the dummy for mild symptoms, there was little evidence on the
effectiveness of treatments in more severe NVP/HG. The reviews also suggested that, in addition to
the use of objective symptom scoring systems, clearly defined outcomes were required so that future
trials could be compared using meta-analyses. Furthermore, although the available evidence indicated
that these treatments were likely to be safe, more research was needed to clarify this.
Many women with severe NVP/HG who fail to respond to first-line antiemetic therapy (e.g. histamine
receptor or dopamine receptor antagonists) will require a hospital review and second-line antiemetic
medication. The RCOG recommends a 5-hydroxytryptamine (5-HT) receptor antagonist (ondansetron)
or a dopamine receptor antagonist (metoclopramide or domperidone) as second-line therapy.12 Our
review identified no trials involving domperidone and one trial showing comparable improvements
in nausea and vomiting with metoclopramide and promethazine (a histamine receptor antagonist).16
The evidence available for ondansetron was predominantly at high or unclear risk of bias. Two
trials were identified comparing ondansetron with metoclopramide.17,18 Kashifard et al.17 compared
ondansetron [4 mg per os (p.o.) three times per day] with metoclopramide (10 mg p.o. three times per
day) in 83 women. Over the 14 days of the trial, the ondansetron group had lower vomiting scores
than the metoclopramide group, but there was no difference in nausea scores. Abas et al.18 compared
ondansetron (4 mg intravenously three times per day) with metoclopramide (10 mg intravenously three
times per day) in 160 women. Symptom improvement was seen in both groups, with no evidence of
difference between groups at 8, 16 or 24 hours.
The primary research recommendation from our HTA evidence synthesis was the need for a RCT,
with an economic evaluation, to determine which second-line hospital-prescribed therapy, in addition
to i.v. rehydration, should be adopted as mainstream provision in the UK NHS. In response to this
recommendation, the HTA programme sought to commission research to determine what was the most
effective drug regimen for women with severe NVP requiring secondary care. Specifically, the brief
called for a trial comparing both 5-HT receptor antagonists and dopamine receptor antagonists
(interventions) with dummy 5-HT receptor antagonists and dopamine receptor antagonists (comparators)
in a double-dummy, double-blind controlled factorial trial. The EMPOWER (EMesis in Pregnancy –
Ondansetron With mEtoClopRamide) trial was undertaken to answer this research question.
Aims and objectives
Main trial aims
This trial aimed to determine which hospital-prescribed therapy [metoclopramide (metoclopramide
hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron
(ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus
GmbH, Hameln)], in addition to i.v. rehydration, should be adopted as the mainstream second-line
treatment of severe NVP by the UK NHS when standard first-line treatment has failed. To achieve
these aims, we set the following objectives.
Primary objectives
To determine whether or not, in addition to i.v. rehydration, ondansetron compared with no ondansetron
and metoclopramide compared with no metoclopramide reduced the rate of treatment failure up to
10 days after initiation.
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Secondary objectives
To determine whether or not, in addition to i.v. rehydration, ondansetron compared with no ondansetron
and metoclopramide compared with no metoclopramide:
l improved symptom severity at 2, 5 and 10 days after intervention initiation
l improved quality of life at 10 days after intervention initiation
l had an acceptable side effect and safety profile.
In addition, we also aimed to estimate the incremental cost per treatment failure avoided and the net
monetary benefits from the perspective of the NHS and women.
Internal pilot and qualitative trial objectives
Owing to uncertainty around the willingness of pregnant women to be recruited into a complex drug
trial, an internal pilot phase was incorporated alongside a qualitative substudy. The main objectives of
the pilot phase were to assess the feasibility of recruitment and rates of retention in those randomised.
The qualitative component aimed to improve our understanding of why women did or did not consent
to participation in the trial.
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This was a multicentre, double-dummy, randomised, double-blinded, dummy-controlled 2 × 2 factorial
trial with an internal pilot phase. Women attending hospital with severe NVP who experienced little or
no improvement while taking first-line anti-sickness medication were invited to participate. Participants
were randomised in a 1 : 1 : 1 : 1 ratio to receive active metoclopramide and dummy ondansetron;
dummy metoclopramide and active ondansetron; active metoclopramide and active ondansetron;
or dummy metoclopramide and dummy ondansetron. The trial aimed to compare whether or not,
in addition to i.v. rehydration, ondansetron compared with no ondansetron and metoclopramide
compared with no metoclopramide reduced the rate of treatment failure up to 10 days after
initiation of treatment. The trial included an economic evaluation and a qualitative component.
Internal pilot
It was planned that there would be an internal pilot phase involving up to eight sites (subsequently
extended to up to 15 sites) followed by a main phase with an additional seven to nine sites
(22–24 sites in total).
To progress from the pilot trial to the main trial, 59 participants needed to be recruited within
6 months, with ≥ 40 participants retained to day 10.
Participants
The trial recruited women aged ≥ 18 years who were < 17 weeks’ gestation and had attended a secondary
care service suffering from severe NVP or HG, and who had received previous treatment with a first-line
antiemetic therapy in the current pregnancy with little or no sustained benefit. Potential participants were
first approached by the clinical staff on duty when they attended hospital for treatment. Participants
presented at gynaecology/early pregnancy clinics, maternity assessment units (MAUs) or accident and
emergency (A&E) departments. The trial was introduced to the participant and permission was sought
for someone in the research team to approach them and provide more information about the trial.
Patients who expressed an interest in taking part were provided with a copy of the participant information
sheet (PIS). Those still interested after reading the information provided were then assessed for eligibility.
Screening
Screening logs were completed at recruiting sites to record reasons for patient ineligibility and for declining
participation. In August 2018, the screening logs were extended to collect information on prior use of trial
drugs in the current pregnancy. Confirmation of eligibility was performed by a General Medical Council
(GMC)-registered medically qualified doctor who was trained in good clinical practice (GCP).
Eligibility
The eligibility criteria that were initially used during the trial are listed below.
Inclusion criteria
l Pregnant women suffering from severe NVP.
l Gestation of < 17 weeks.
l Had previously taken first-line antiemetic treatment (cyclizine, chlorpromazine, promethazine or
prochlorperazine, as recommended by RCOG12) as prescribed, over at least 24 hours with no
sustained improvement in symptoms.
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l Age ≥ 18 years.
l Able to give informed consent.
l Able to read/understand written English.
Exclusion criteria
l Allergy/hypersensitivity to any of the study drugs.
l Prior treatment with trial drugs in this pregnancy.
l Pre-existing diagnosis of a medical condition: type 1 or 2 diabetes mellitus, chronic kidney
disease stages 3–5, Graves’ disease, significant cardiac disease (including long QT syndrome),
phaeochromocytoma, epilepsy (or other seizure disorder) or severe liver disease (alanine
transaminase or aspartate transaminase of > 2.5 times the upper limit of normal pregnancy).
l Moderate renal impairment diagnosed during pregnancy (definition: serum creatinine level of
> 100 µmol/l).
l Severe diarrhoea [definition: > 10 loose, watery stools in 1 day (24 hours)].
l Hypokalaemia (definition: serum potassium level < 3 mmol/l).
l Pre-existing diagnosis of hypomagnesaemia.
l Vomiting caused by another underlying condition/infection.
l Concomitant use of apomorphine or serotonergic drugs [e.g. selective serotonin reuptake inhibitors
(SSRIs), monoamine oxidase inhibitors and lithium].
l Confirmed diagnosis of severe lactose intolerance (e.g. patients with rare hereditary problems of
galactose intolerance, Lapp lactase deficiency or glucose–galactose malabsorption).
Early in the period of screening and recruitment, it became apparent that the exclusion criterion ‘Prior
treatment with the trial drugs in this pregnancy’ was causing high rates of ineligibility across all sites.
After review by all trial oversight bodies, the wording of this criterion was changed to:
l received either i.v. ondansetron or metoclopramide
l received either p.o. ondansetron or metoclopramide for > 72 hours (with or without i.v. rehydration).
The updated eligibility criteria were implemented at sites on 20 February 2019.
Women who presented with severe diarrhoea and met the inclusion criteria but were subsequently found
to have a serum potassium level of > 3mmol/l could still be offered participation in the EMPOWER trial.
Women who presented with severe NVP routinely had urea and electrolytes assessed clinically. In the
absence of severe diarrhoea, women could still be approached, consented and given trial treatments
before urea and electrolyte results were available; if the serum potassium level was subsequently
found to be low (< 3 mmol/l), the hypokalaemia had to be corrected quickly with i.v. supplementation,
but there was no need to withdraw them from the trial.
Consent
A copy of the PIS was provided to eligible women by the local site team. Patients were first provided
with a short PIS to provide them with an overview of the trial. Those interested after reading the short
PIS were provided with a copy of the full PIS. Potential participants were given a minimum of 1 hour
to review the PIS. During this time, an i.v. cannula could be sited, blood could be taken for necessary
clinical tests and i.v. fluids could be commenced. Consent was received by a GMC-registered medically
qualified doctor trained in GCP. Women who agreed to participate were asked if they would also be
willing to take part in an optional qualitative interview.
Women who declined to participate in the trial itself were still asked if they would like to be
approached to participate in the qualitative interviews.
Once consent had been received, randomisation was undertaken.
METHODS
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Schedule of events
The schedule of events for the trial is shown in Table 1 and a participant’s journey through the trial is
shown in Figure 1.
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✗ ✗ ✗ ✗ ✗ ✗
Pregnancy outcomes ✗ ✗
EPDS, Edinburgh Postnatal Depression Scale; IMP, investigational medicinal product; NVPQoL, nausea and vomiting
during pregnancy quality of life; PUQE, Pregnancy Unique Quantification of Emesis; STAI, State–Trait Anxiety
Inventory; VAS, visual analogue scale.
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Once a participant was consented and randomised, the trial medication was dispensed by the research
team and i.v. medication commenced as soon as possible. Baseline questionnaires were also completed
by the participant.
Women aged ≥ 18 years who were < 17 weeks’ gestation attending secondary care suffering with moderate
to severe NVP/HG who had previous treatment with a first-line antiemetic therapy with little to
no sustained benefit
Women assessed as eligible for the EMPOWER trial were approached for study participation: PIS provided
i.v. fluids, blood tests, routine observations and PUQE commenced/collected as per usual care




































• Dispensing and commencing trial drug
• Demographics
• Medical history
• Baseline questionnaires – NVP QoL, EPDS, STAI and Material Social Support Scale
• Access blood tests, routine observations and PUQE score collected as per usual care
No improvement 12-hour assessment
Patient improved
Treatment fail: participant withdrawn
from the study IMP and placed on 
third-line antiemetic treatment
48-hour follow-up (in person or by telephone):
5-day follow-up (telephone call):
10-day follow-up (telephone call):
• Compliance of study IMP
• Reminder to complete questionnaires (PUQE and VAS for nausea)
• Adverse events review
• Concomitant medications
• Compliance of study IMP
• Reminder to complete questionnaires (PUQE and VAS for nausea)
• Adverse events review
• Concomitant medications
• Compliance with study IMP
• Reminder to complete questionnaires (PUQE, VAS for nausea,
    NVP QOL, EPDS, STAI, Participant Resource Use questionnaires
    and Contingent Valuation Survey)
• Adverse event review
• Concomitant medications
Follow-up data collection at 20 weeks’ gestation via
chart review


















































































































FIGURE 1 Trial flow chart. EOI, expression of interest; EPDS, Edinburgh Postnatal Depression Scale; IMP, investigational
medicinal product; PUQE, Pregnancy Unique Quantification of Emesis; STAI, State–Trait Anxiety Inventory; VAS, visual
analogue scale.
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While in hospital, participants were provided with a trial pack that included the questionnaires to
be completed at 2, 5 and 10 days, a trial diary to record adverse events (AEs) and concomitant
medications, and a trial identification (ID) card, including emergency contact details, for participants to
carry with them while participating in the trial. All participants, unless they had been discharged from
hospital, were reviewed at 12 hours to assess responsiveness to trial medication. If the participant had
not responded to the trial medication within the first 12 hours of treatment, trial medication was
stopped and the participant was placed on further treatment outside the trial.
Follow-up with the participants took place at 2 days post first dose of trial medication, at 5 days and at
the final follow-up questionnaires at 10 days. These follow-ups were completed via telephone call by
members of the research team. Participants were also followed up at 20 weeks’ gestation and post
birth, but via medical chart review.
Participant expenses
No expenses were incurred by participants travelling for trial visits. Follow-up was completed via
telephone or via review of the participant’s medical chart.
Details of the trial interventions
Participants were randomised to one of four groups. The groups that a participant could be allocated to
are outlined below, along with the dose and route of administration:
l metoclopramide [10 mg three times daily (i.v. and p.o.)] and dummy ondansetron (i.v. and p.o.)
l ondansetron [4 mg three times daily (i.v. and p.o.)] and dummy metoclopramide (i.v. and p.o.)
l metoclopramide [10 mg three times daily (i.v. and p.o.)] and ondansetron [4 mg three times daily
(i.v. and p.o.)]
l double dummy three times daily (i.v. and p.o.).
Delivery of the trial interventions
Participants initially received trial medication intravenously; trial medication could be administered
intravenously for up to 4 days. Once the participant was able to tolerate fluids, they were converted
to oral tablets. The oral medication was taken at the same frequency and dosage as the i.v. formulation.
Both the i.v. and the p.o. medication were supplied in the same trial medication kit to prevent the
necessity for a double prescription. The total duration of treatment for each participant was 10 days.
Treatment compliance
Participants took trial medication for a maximum of 10 days. Participants were contacted at 2, 5 and
10 days and compliance regarding taking oral medication was checked with participants at these time points.
Participants were asked to return all unused oral trial medication and all packaging (even if empty) to
the trial team at each site. A stamped, addressed envelope was provided as part of the trial pack for
participants to return medication after they had taken their final dose at day 10. Participants were
reminded by the research team to post trial medication back to the site, but if they forgot there was
the option to bring it with them to their next clinical appointment. The site team counted all returns
(both tablet returns received from the participant and leftover ampoules returned to the pharmacy)
and recorded these on the trial database.
Withdrawals
Participants had the right to withdraw from the trial at any time without having to give a reason;
however, if provided, the reason for withdrawal was recorded. Participants remained in the trial unless
they withdrew consent or the local principal investigator (PI) felt that it was no longer appropriate for
the participant to continue. For participants who chose to withdraw, permission was sought to allow
the research team to collect routinely collected data from their medical records. If the participant did
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not agree to this, only the data collected up to the point of withdrawal were retained. Participants who
withdrew from the trial were not replaced.
Sites
The EMPOWER trial was conducted at 12 NHS sites in England. Site set-up commenced in October 2017.
Initially, seven sites were set up:
1. Newcastle upon Tyne NHS Foundation Trust
2. City Hospitals Sunderland Hospitals NHS Trust (now South Tyneside and Sunderland NHS
Foundation Trust)
3. South Tees Hospitals NHS Foundation Trust
4. Bradford Teaching Hospitals NHS Foundation Trust
5. Leeds Teaching Hospitals NHS Trust
6. Birmingham Women’s and Children’s NHS Foundation Trust
7. Guy’s and St Thomas’ Foundation Trust.
Five further sites were set up during the extended internal pilot:
1. Pennine Acute Hospitals NHS Trust
2. University Hospitals of North Midlands NHS Trust
3. St George’s University Hospitals NHS Foundation Trust
4. Nottingham University Hospitals NHS Trust
5. Portsmouth Hospitals NHS Trust.
Outcome measurement
Primary outcome
The primary end point was the number of participants experiencing a treatment failure. Treatment
failure was defined as the need for further treatment if a participant’s symptoms had worsened
between 12 hours and 10 days post initiation of treatment. Where further treatment was required,
a participant should have been placed on third-line antiemetic treatment (i.e. high-dose ondansetron
or corticosteroids) unless the clinician considered further second-line treatment more appropriate.
Secondary outcomes
The following secondary patient-reported and clinical outcomes were collected:
l Symptom severity, as measured by the Pregnancy Unique Quantification of Emesis (PUQE) score19–21
(see Appendix 1), collected at baseline and at 2, 5 and 10 days post initiation of treatment.
l Severity of nausea, as measured by a visual analogue scale (VAS)17 for nausea, collected at 48 hours
and at 5 and 10 days post initiation of treatment.
l Quality of life, as measured by the health-related nausea and vomiting during pregnancy quality-of-life
(NVPQoL)22 questionnaire (see Appendix 2), collected at baseline and 10 days post treatment
commencing.
l Depression, as measured by the Edinburgh Postnatal Depression Scale (EPDS)23 (see Appendix 3),
collected at baseline and 10 days.
l Anxiety, as measured by the six-item State–Trait Anxiety Inventory (STAI),24 collected at baseline
and 10 days [see https://oml.eular.org/sysModules/obxOml/docs/ID_150/State-Trait-Anxiety-
Inventory.pdf (accessed September 2021); the six items used were items 1, 3, 6, 15, 16 and 17].
l Social support, as measured by the Maternity Social Support Scale (MSSS)25 (see Appendix 4),
collected at baseline.
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l Clinical indicators of antiemetic effectiveness:
¢ the number of participants experiencing a treatment failure at 2 days
¢ relapse rate at 5 and 10 days (defined as a PUQE score of ≤ 6 at 2 days followed by an increase
to > 12 at 5 or 10 days)
¢ remission rate at 10 days [defined as a PUQE score of ≤ 6 at 2 days with return to persistent
symptoms (PUQE score of ≥ 7) at 10 days]
¢ readmission rates (the number of participants readmitted with NVP within 10 days of
recruitment and between 10 days of recruitment and 20 weeks of pregnancy)
¢ total inpatient days related to NVP between recruitment and 20 weeks of pregnancy and between
20 weeks of pregnancy and delivery
¢ additional antiemetic use.
l Side effects and AEs – participants were asked about side effects/AEs that they experienced at 2,
5 and 10 days post treatment commencing. Severity was graded using the Common Terminology
Criteria for Adverse Events (CTCAE).26
l Pregnancy and neonatal outcomes – the numbers of women experiencing miscarriage, TOP and
stillbirth were recorded. For each infant born, the mode of delivery, gestational age at delivery and
birthweight were collected. Information on congenital anomalies detected prior to discharge was
also collected. In the case of multiple births, this information was collected for each infant.
l Key economic outcomes:
¢ costs to the NHS and to participants (see Appendix 5)
¢ willingness to pay (WTP) (see Appendix 6) for the benefits of antiemetic treatment
¢ incremental cost per treatment failure avoided and net monetary benefits.
All data fields were locked on 5 December 2019, with the exception of fields relating to pregnancy
outcome data, AEs/serious adverse events (SAEs), deviations/violations, investigational medicinal
product (IMP) accountability and concomitant medication, which were locked on 9 April 2020.
Sample size calculation
As per the 2 × 2 factorial design, the intention was to have two main comparisons:
1. active metoclopramide (with either active or dummy ondansetron) and dummy metoclopramide
(with either active or dummy ondansetron)
2. active ondansetron (with either active or dummy metoclopramide) and dummy ondansetron
(with either active or dummy metoclopramide).
An antiemetic failure rate of 10% was assumed based on prior ondansetron studies (with rates of 13%
at 48 hours27 and 7% at 5 days28) and our pilot RCT of midwife-led outpatient care,29 in which 10% of
women had failure of a second-line antiemetic (primarily metoclopramide). With 266 participants in
each comparison (i.e. 133 in each of four treatment combinations, 532 in total) and assuming no
interaction between the two active treatments, it was estimated that we would have 90% power to
detect an increase in failure rate from 10% in either antiemetic group to 20% in either dummy group
(based on a two-sided test at the 5% level). This effect size was felt to be of clinical relevance to
applicants and sufferers.
As the primary outcome was treatment failure between 12 hours and 10 days post treatment
initiation, we anticipated obtaining outcome data from at least 90% of participants. Therefore, to
account for a 10% dropout prior to assessment of the primary outcome, it was planned to recruit
600 patients (150 in each randomised group). Sample size calculations were performed using power
twoprop in Stata® version 14 (StataCorp LP, College Station, TX, USA).
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Randomisation
Randomisation was carried out centrally by the Newcastle Clinical Trials Unit (NCTU) using a
secure web-based system. Patients were randomised on a 1 : 1 : 1 : 1 basis using computer-generated
random permuted blocks of size four and stratified by site to receive (1) metoclopramide and dummy
ondansetron; (2) ondansetron and dummy metoclopramide; (3) metoclopramide and ondansetron;
or (4) double dummy. Randomisation was performed by local research staff, who were delegated this
task via the delegation log. The randomisation system generated a unique participant trial identifier
and allocated a pack number to be dispensed to the participant. Pre-populated prescriptions were
generated by the randomisation system.
Unblinding
The EMPOWER study was a double-blind trial. It was not planned that participants would be routinely
unblinded once they had completed trial treatment.
However, participants could be unblinded in a valid medical emergency or for safety reasons where it
was necessary for a treating clinician to know which treatment the participant had been receiving.
Emergency unblinding could be carried out by the site PI (or another member of the team delegated
this responsibility via the delegation log) by accessing the 24-hour randomisation system. A set of back-up
sealed code-break envelopes were also held at sites in case of system failure or lack of availability of a
delegated individual.
Following discussions with the Trial Steering Committee (TSC), a decision was made to fully unblind all
trial medications after the trial was stopped, allowing PIs to notify participants of the medication that
they received during the trial.
Statistical analysis
A statistical analysis plan was drafted and finalised prior to data lock. Given that the trial closed to
recruitment at the end of the pilot phase, only descriptive summaries of the data have been reported.
No efficacy analyses have been undertaken owing to the small sample size. Had the internal pilot trial
progressed to a full trial, the group comparisons would have been used as originally intended for this
factorial trial. However, given that the pilot data are being reported, the focus of the results is on
feasibility outcomes and, therefore, data have been summarised by randomised treatment group.
The progress of all participants through the trial is presented using a Consolidated Standard of
Reporting Trials (CONSORT) flow diagram, including the number of screened and eligible patients.
Rates of eligibility and recruitment are summarised by site. Reasons for ineligibility or non-participation
have been tabulated.
Baseline data are summarised descriptively. Numbers (with percentages) for categorical variables
and medians (with ranges) for continuous variables were summarised by randomised treatment group
and overall.
A summary of trial medication received is reported using numbers (with percentages) by randomised
treatment group and overall. Reasons for premature treatment discontinuation are described.
Primary and secondary outcome measures were summarised descriptively by randomised treatment
group and overall. Data are presented following the intention-to-treat principle, with participants
retained in the groups to which they were randomised. The primary outcome measure of treatment
failure between 12 hours and 10 days was tabulated. The rate of treatment failure [with 95%
confidence intervals (CIs)] was calculated out of those evaluable; participants choosing to withdraw
from trial treatment before 12 hours and participants choosing to withdraw from the trial without
allowing further use of routine data, between 12 hours and 10 days or without prior documented
treatment failure were not considered evaluable. Readmissions for NVP, inpatient days related to NVP
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and additional antiemetic use were tabulated out of those evaluable. Relapse at day 5 or day 10 and
remission at day 10, as defined by changes in the PUQE score, were tabulated out of those with completed
PUQE questionnaires at day 2 and also at days 5 and 10. The completeness of participant-reported
questionnaires was tabulated for each measure. Questionnaires were considered to be completed only
if responses were available for all items. Questionnaire scores at each assessment point were summarised
descriptively using numbers (with percentages) for categorical variables and medians (with ranges) for
continuous variables. For each questionnaire, a score was calculated only if all items were completed.
No imputation of missing data were used.
Pregnancy and neonatal outcomes were summarised descriptively, by randomised treatment group
and overall, as numbers (with percentages) for categorical variables and medians (with ranges) for
continuous variables. For multiple births, neonatal outcomes were summarised for each infant born.
Analyses were conducted in Stata® version 16.
Sources of bias
The primary outcome measure of treatment failure, defined as the need for further treatment because
participants’ symptoms had worsened between 12 hours and 10 days, is likely to be partially subjective.
This risk of ascertainment bias was reduced by the trial being double blinded, so neither the participant
nor the clinical team were aware of the allocated treatment. Secondary outcome measures, including
participant-reported questionnaires, were also completed or collected by participants, clinicians or
research staff blinded to treatment allocation.
As far as possible, the reasons for eligible patients declining participation were recorded; however,
patients were free to decline without giving a reason. It is possible that those who were too unwell
to consider the trial information were more likely to decline than those with less severe symptoms;
however, randomisation should have ensured that the treatment groups were balanced with respect
to severity of NVP at baseline. The PIS illustrated the uncertainty and lack of high-quality evidence
around the effectiveness of the trial drugs for women with NVP, and women had to be willing to be
allocated to any treatment group, including double dummy.
Patients were not considered evaluable for the primary outcome measure if they withdrew from trial
treatment prior to 12 hours or fully withdrew from the trial between 12 hours and 10 days without
prior treatment failure. This could have introduced bias if participant withdrawal related to the
effectiveness of trial treatment. Reasons for withdrawal were obtained where possible; however,
participants were free to withdraw from the trial at any time without giving a reason.
Missing outcome data at follow-up, particularly for participant-reported outcome measures, could have
introduced bias if data were not missing at random. Had the trial progressed to a main trial, patterns of
missing data would have been explored and multiple imputation methods considered.
Health economic evaluation
The health economics analysis plan was finalised and approved before data lock. Given that the trial
closed after the pilot phase, the proposed evaluation was no longer appropriate and the economic
analysis was confined to two primary components:
1. Presentation of health service resource use data in the form of summary statistics.
2. Information on health-care resource use was collected via electronic case report forms (eCRFs)
(for concomitant medication) and participant-completed health-care utilisation questionnaires
(A&E attendance, receipt of primary care and other NHS/Personal Social Services care services), and
was completed at 10 days post randomisation. Data on participant-related costs were also collected
via the health-care utilisation questionnaire at the day 10 follow-up assessment. Participants were
asked to provide information relating to the purchase of private health care or personal care.30
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An analysis of the completeness of the resource use data collected was conducted using descriptive statistics
to calculate the number and percentage of participants, with data available for each resource item.
3. Presentation of WTP data in the form of summary statistics.
4. Participants were asked to directly express their WTP for a good service using a contingent
valuation (CV) questionnaire. To ascertain their preferences, participants were presented with
hypothetical scenarios and were asked how much they would be willing to pay to improve symptom
severity for a 10-week period. The hypothetical scenarios were informed by input from women with
experience of NVP, the literature and other experts. For a given level of income, a higher WTP value
indicated that individuals derived greater benefit from a reduction in symptom severity.
Information gathered via the CV questionnaires is presented as mean [standard deviation (SD)] and
median [interquartile range (IQR)] WTP amount to improve symptom severity over a 10-week period.
The maximum and minimum WTP values for each of the four randomised treatment groups have also
been reported.
All information was summarised by randomised treatment groups and overall. The analysis was
conducted using Stata® version 15.
Qualitative evaluation
As part of the protocol for the EMPOWER clinical trial, an evaluation of women’s views of the
acceptability of the trial design was carried out with the aim of improving our understanding of why
women did, or did not, consent to randomisation and participation in the trial.
Recruitment to the qualitative study, as with the pilot trial, progressed slowly. The eligibility criteria
were broadened in February 2019, as many women were found to be ineligible because of prior use
of trial medication. As a result, the number of women available to approach for the qualitative study,
particularly of decliners, was limited. In consultation with the TSC, it was therefore agreed to extend
the qualitative component to include research staff to undertake a wider exploration of factors
influencing trial recruitment.
Recruitment of study participants
Patient recruitment
Women who had been screened and were found to be eligible, and had accepted or declined to
participate in the trial, were approached for recruitment to the qualitative substudy. Potential recruits
were given a copy of the separate PIS and expression-of-interest (EOI) form. To be considerate to
patients who were possibly still suffering from NVP, attempts by the qualitative researcher to contact
and interview women were confined to the period between the 14th and the 28th day after the initial
approach to participate in the EMPOWER trial. Brief 10- to 15-minute interviews were conducted with
women who returned the form and were contactable (see Appendix 7). An option of an e-mail interview
was also provided in case women were too ill to converse. Consent was obtained over the telephone,
recorded and transcribed. A copy of their consent form, filled in by the researcher on their behalf, was
sent to participants by e-mail or by post.
Research staff recruitment
Research staff contact details were accessed via NCTU. E-mails about the staff trial (with the PIS and
consent form attached) were sent to staff who had screened or recruited women to the trial. Research
midwives/nurses directly involved in trial recruitment, and site PIs who were interested in participating
in the interviews, returned the consent form by e-mail or agreed to consent taken over the telephone.
The large majority who were contacted were willing to participate and the telephone interviews lasted
between 20 and 30 minutes (see Appendix 8).
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Interview methods
To keep to the short period of time assigned for the patient interview, the topic guide was made up of
a grid of questions and possible answers. This allowed the interviewer to quickly adapt the interview to
the specific experiences of the woman being interviewed and allowed each participant’s priority topics
to shape the conversation. The interview was semistructured, which allowed opportunities for women
to expand on their answers wherever possible about positive and negative reasons for participating.
The main questions in the grid were:
l What did you think about when you were first asked to take part in the trial?
l Why did you/did not you want to take part in the trial?
l Did the way in which you were invited to take part affect your decision?
l Was there anything about the trial itself that made you want/not want to take part?
Semistructured interviews were conducted with at least two research nurses/midwives and the
PI from each trial site that had recruited at least one participant to the trial. Interviews covered
the following topics: experiences of trial set-up and recruitment, difficulties and progress through
the trial, and suggested improvements. They took place over the telephone at times convenient
to the staff.
In the case of the research staff, a grounded theory approach with constant comparison during the data
collection phase was adopted;31 although an interview topic guide was followed, this was adapted as
findings from research staff interviews emerged and needed further exploration. A second topic guide
was then designed based on these findings for the PIs because of their managerial responsibilities
and oversight of the trial. The following were further topics that were explored in the course of the
interviews with PIs:
l proportion of women referred from A&E department
l attempts to raise the profile of the trial with local general practitioners (GPs)
l effect of the protocol amendment on recruitment
l women with language difficulties
l antidepressant use as a contraindication
l involvement of research staff in the care of patients being recruited
l awareness that trial drugs were being used in primary care.
An opportunity for triangulation with the patient data also arose as staff were able to describe
particular cases of screening and recruitment that could be of interest to the trial. Recruitment
to the patient group was more limited than originally anticipated. Nevertheless, data saturation
was reached, that is the data obtained allowed us to reach the point at which no issues needed
further confirmation or exploration, and no new themes emerged from either the patient or the trial
staff data analysis.
Qualitative data management
Sound files of all interviews, Microsoft Word (Microsoft Corporation, Redmond, WA, USA) files of their
transcriptions and Microsoft Word files of the four e-mails were stored on a password-secure server.
The transcripts of patients and research staff were checked for accuracy, anonymised and entered into
qualitative data management software NVivo 12 (QSR International, Warrington, UK) for indexing
and retrieval. Using the software, cases were created of the eight trial sites, with patient and clinician
interviews grouped together for cross-checking. The presentation of results based on site characteristics
was discounted because of the risk of participants being identifiable.
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Qualitative data analysis
The data were analysed using a generative thematic approach,32 in which codes were developed
inductively from the reading and re-reading of transcripts, to form an initial coding framework that
was revised, expanded or collapsed as the analysis progressed. The analytical process followed the
first four stages described by Braun and Clarke:33
l familiarisation with the data – reading and re-reading of a sample of transcripts to identify and
agree descriptive codes (ML and RG: one meeting on patient data and another on trial staff data)
l coding the data – coding the data according to an initial coding frame and revising the coding frame
as further interviews were analysed (ML)
l searching for themes – analysis of the text coded in descriptive codes to determine at an
interpretive level the themes that would best capture the findings from the data (ML)
l reviewing the themes – data analysis team meeting to review possible themes with a clinician chief
investigator (SCR) and medical sociologist co-investigator (RG).
At a second data analysis team meeting, two broad themes were agreed for further analysis, that is the
‘hurdles’ to and ‘enablers’ of the trial process. Considering the complexity of the data with respect to
the differences in the sample groups, it was decided that the best way to present the data was to chart
the findings according to the framework approach.34,35 The data were charted under the following groups:
l patients who accepted participation
l patients who declined participation
l research midwives/nurses
l PIs.
This enabled triangulation between the different types of experiential knowledge within the data
sets overall.
In a third data analysis team meeting, the qualitative findings according to the two broad themes of
‘hurdles’ and ‘enablers’ were presented using illustrative quotations in a Microsoft Excel® spreadsheet
(Microsoft Corporation, Redmond, WA, USA). A decision was made to present the key themes in the
data with selected quotations from the Microsoft Excel® spreadsheet in the text itself as in a standard
qualitative report. This allowed a clearer link between the discussion of the themes and the available
evidence from the qualitative data.
This descriptive analysis was complemented by a more interpretative strand of analysis in which the
qualitative data were presented according to sociological, concept-led themes relating to ‘pathways’
and ‘boundaries’, and ‘ethics of care’. The data findings under themes that related to process
evaluation, such as recruitment complexity and staff morale, were also presented because they had
emerged from the coding of research staff interviews.
Definition of end of trial
The end of trial was defined as the date that the last infant born to an EMPOWER trial participant was
discharged from hospital.
Trial management
The Trial Management Group (TMG) was responsible for overseeing the day-to-day management of
the trial. TMG meetings were well attended throughout and involved the chief investigator, statisticians,
health economists, qualitative researchers, pharmacy representatives, sponsor representatives, trial
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management team members, patient contributors and local co-applicants. The TMGmet regularly throughout
the trial to ensure adherence to the trial protocol and monitor the conduct and progress of the trial.
Data management
The trial database was built by the trial data manager with input from the TMG using MACRO™
(Elsevier, Amsterdam, the Netherlands). The randomisation system and stock management were
set up by the trial data manager using the NCTU randomisation system.
All visit data were entered into the MACRO™ database at each site by the local research team. Baseline
questionnaire data were entered by local site staff. The 2-day, 5-day and 10-day questionnaires were
returned to NCTU by participants and data entry was completed by the central trial team. The central
team contacted participants by post after they had completed day 10 to remind them to return the
questionnaires and unused IMP/packaging if they had not already done so. One further letter was sent
approximately 2 weeks later if the questionnaires had still not been received by the central team.
Serious adverse event data were sent to the central trial team by secure e-mail and then entered
centrally into the MACRO™ database.
Essential data will be retained for a period of at least 15 years following the close of the trial in line
with sponsor policy and the latest directive on GCP (2005/28/EC). Data were handled, digitalised and
stored in accordance with the Data Protection Act 199836 and the Data Protection Act 2018.37 In line
with GDPR (General Data Protection Regulation), the sponsor acted as the data controller and NCTU
acted as the data processor for this trial.
It was planned to transfer outcome data at the end of the trial to the UK Teratology Information
Service (UKTIS) national database for participants who had consented to this. This was to be retained
(under section 25138) for the purpose of surveillance. However, given the limited data available, a
decision was made by the TMG, in consultation with UKTIS, not to transfer the data.
Data monitoring, quality control and assurance
Monitoring of trial conduct was completed using a mix of central review and on-site monitoring visits
to ensure that the trial was conducted in accordance with the protocol and GCP.
Data were monitored centrally throughout the trial by the data manager and checked regularly for
completeness, and any discrepancies were queried with sites using the built-in data clarification
request function in MACRO™. Validations built into the database flagged potential errors with dates
and out-of-range values. A full list of built-in validations was detailed in the data validation plan.
Source data verification was conducted by the trial manager during the on-site monitoring visits,
as set out in the monitoring plan.
A data quality report was produced and reviewed at TMG meetings. Data from MACRO™ were
compared with data from the NCTU randomisation system to ensure consistency.
An independent Data Monitoring Committee (iDMC) was convened to monitor safety. The iDMC met
at the start of the trial and three times throughout the trial.
A TSC was established to provide overall supervision of the trial. The TSC consisted of an independent
chairperson, two further independent clinicians, an independent statistician, an independent health
economist, two independent lay representatives, a patient contributor and the chief investigator.
Other members of the TMG attended as required. The committee met five times throughout the trial.
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Serious adverse event reporting
All AEs and adverse reactions (ARs) occurring from the start of administration of the IMP through to
24 hours post last IMP dose were recorded via the eCRF AE page and documented in the participant’s
medical records.
Each participant was assessed at baseline and any conditions or symptoms that they were currently
experiencing were recorded in the participant’s medical records and graded using the CTCAE.
During follow-up, participants were asked about any new or ongoing symptoms, and sites followed the
below process:
l For symptoms previously reported at baseline –
¢ If the CTCAE grading remained the same or better, the symptom did not need to be recorded as
an AE or AR. Symptoms were still documented in the patient’s medical records.
¢ If the CTCAE grading was worse, this was recorded as an AE or AR in the eCRF AE page and
documented in the patient’s medical records.
l For new symptoms not recorded at baseline, these were recorded as an AE or AR and graded
using CTCAE. These were recorded via the eCRF AE page and were documented in the patient’s
medical records.
All AEs and ARs that met the definition of serious were regarded as a SAE or serious adverse reaction
(SAR) and needed to be reported as part of the trial. SAEs and SARs were also collected from the start
of administration of the IMP through to 24 hours post last IMP dose. Thereafter, any SAR that came to
the attention of the site team had to be reported up until the point of trial closure. All deaths were to
be reported as SAEs irrespective of the cause.
All potential reactions were assessed for expectedness using the reference safety information. The
reference safety information was contained in section 4.8 of the Summary of Product Characteristics
for each of the four medications used in this trial (metoclopramide tablets, i.v. metoclopramide,
ondansetron tablets and i.v. ondansetron).
Amendments to the trial protocol
Following receipt of a favourable opinion of the trial protocol from the National Research Ethics
System, substantial amendments were submitted and received Health Research Authority (HRA)
approval and favourable Research Ethics Committee (REC) opinion [and Medicines and Healthcare
products Regulatory Agency (MHRA) approval where applicable].
In summary, these were as follows:
l Amendment 1 – protocol V2.1, 26 February 2018. This was updated on advice from the TSC
regarding treatment options for those who fail on EMPOWER trial treatment: some clarifications
regarding eligibility criteria were also provided.
l Amendment 2 – protocol V3.0, 11 September 2018. This was updated to include staff participants in
qualitative interviews.
l Amendment 3 – protocol V4.0, 15 November 2018. The protocol was updated to reflect the
extension of the pilot phase and to update the eligibility criteria to include women who had
received suboptimal treatment with ondansetron or metoclopramide based on findings during the
pilot phase.
METHODS
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l Amendment 4 – protocol V5.0, 19 March 2019. This included an update to the exclusion criteria
(amended in the last update to provide clarity following feedback from sites); provision of the
option to collect PUQE, VAS and Health Utilisation Questionnaire data by telephone at day 10;
and clarification that participants needed to have been off SSRIs for at least 2 weeks to meet this
eligibility criterion.
Patient and public involvement
Both public co-applicants had suffered from severe NVP during pregnancy. Both contributed to the
design of the trial; specifically, they prioritised the primary outcome and contributed to the selection
of secondary outcomes, the duration of intervention use before assessment for treatment failure and
the overall maximum duration of intervention use. During the trial, both public co-applicants continued
to provide extensive input, including reviewing the design and content of the PIS, designing a one-page
short-form schematic of the PIS, reviewing the design of the WTP questionnaire, helping with the
design and content of the EMPOWER trial website, and providing support to the team regarding the
eligibility challenges faced during the pilot. One co-applicant facilitated a wider review of opinions on
various design elements via an online group of women with previous experience of HG. The two lay
members of the TSC were also engaged throughout and attended TSC meetings and teleconferences,
as well as numerous additional telephone calls and e-mails with the chief investigator and lead
research midwife.
Ethics and governance
The Newcastle upon Tyne Hospitals NHS Foundation Trust was the sponsor for the trial (reference 08367).
The trial received clinical trial authorisation from the MHRA on 22 November 2017 and favourable ethics
opinion from the North East – Newcastle & North Tyneside 1 Research Ethics Committee (reference
number 17/NE/0325) on 30 November 2017. HRA approval was also received on 30 November 2017.
Subsequent research and development approvals were granted by each participating site. Required
approvals were sought and obtained prior to implementation of all substantive protocol amendments.
Trial registration and protocol availability
The trial was registered on the International Standard Randomised Controlled Trials Number (ISRCTN)
registry as ISRCTN16924692 on 8 January 2018.
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A CONSORT flow diagram of participant flow through the trial is shown in Figure 2.
Screening
Between 24 April 2018 and 12 August 2019, 592 patients were screened for eligibility. Table 2
summarises the number of patients screened by site. Overall, 122 (21%) patients were eligible.
The proportion of eligible patients increased from 19% to 22% after the implementation of protocol
version 4.0 to broaden the eligibility criteria around prior use of trial drugs.
Reasons for ineligibility are shown by site in Table 3. The main reason for ineligibility was prior
treatment with trial medication(s) in the current pregnancy (n = 320; 68%).
Further detail on prior use of ondansetron or metoclopramide is shown in Table 4. This information
was collected only from 29 August 2018, once prior treatment with trial drugs was identified as a
barrier to recruitment. Of those ineligible owing to prior exposure to trial drug(s), 83% had received
ondansetron and 17% had received metoclopramide. Prior to protocol version 4.0, in which data on
route of administration were available, 41 (37%) participants had received oral treatment only;
however, only 10 participants were known to have received oral treatment for ≤ 3 days. Where the
source of prescription was known, 57 (24%) participants had received treatment from their GP and the
remaining 179 (76%) participants from secondary care. In those receiving treatment from secondary
care, the main reason for non-recruitment was the lack of availability of research staff (58%), mostly
owing to patients attending out of hours (82%).
Overall, 89 patients were eligible for the trial but were not recruited, with 62 (70%) of those declining
participation. Reasons for eligible patients declining participation are shown in Table 5.
Recruitment
From the 122 eligible patients who were screened, 33 (27%) were randomised into the trial. As per
the 2 × 2 factorial design, participants were randomised to receive active metoclopramide and dummy
ondansetron (n = 8); active ondansetron and dummy metoclopramide (n = 8); active metoclopramide and
active ondansetron (n = 9); or dummy metoclopramide and dummy ondansetron (n = 8) (see Figure 2).
Despite the proportion of eligible patients increasing slightly following the implementation of protocol
version 4.0, the proportion of eligible patients randomised into the trial declined from 38% to 16% (see
Table 2). Of the 12 trial centres open to recruitment, seven enrolled at least one participant into the trial.
Internal pilot
It was initially planned that there would be an internal pilot phase involving up to eight sites followed
by a main phase with an additional 14–16 sites (22–24 sites in total).
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• Ineligible, n = 470
• Declined, n = 62
• Not approached,  n = 16













• Discontinued trial treatment, n = 2
    • Treatment failure, n = 1
    • Other reason, n = 1
• Withdrawn from follow-up, n = 1
    • Allowing use of routine data, n = 0
• Discontinued trial treatment, n = 2
    • Treatment failure, n = 1
    • Other reason, n = 1
• Withdrawn from follow-up, n = 0
• Discontinued trial treatment, n = 3
    • Treatment failure, n = 3
• Withdrawn from follow-up, n = 1
    • Allowing use of routine data, n = 0
• Discontinued trial treatment, n = 3
    • Treatment failure, n = 1
    • Other reason, n = 2
• Withdrawn from follow-up, n = 1
    • Allowing use of routine data, n = 1
• Discontinued trial treatment, n = 2
    • Treatment failure, n = 2
• Withdrawn from follow-up, n = 0
• Discontinued trial treatment, n = 2
    • Treatment failure, n = 2
• Withdrawn from follow-up, n = 0
• Discontinued trial treatment, n = 3
    • Treatment failure, n = 3
• Withdrawn from follow-up, n = 0
• Discontinued trial treatment, n = 1
    • Treatment failure, n = 1
• Withdrawn from follow-up, n = 0
• Discontinued trial treatment, n = 2
    • Treatment failure, n = 1
    • Other reason, n = 1
• Withdrawn from follow-up, n = 1
    • Allowing use of routine data, n = 1
• Discontinued trial treatment, n = 0
• Withdrawn from follow-up, n = 0
• Discontinued trial treatment, n = 0
• Withdrawn from follow-up, n = 0
• Discontinued trial treatment, n = 0
• Withdrawn from follow-up, n = 0
Day 2: seven assessable
PUQE complete, n = 6
Day 5: six assessable
PUQE complete, n = 5
Day 10: six assessable
PUQE complete, n = 3
NVQOL complete, n = 3
Day 10: eight assessable
PUQE complete, n = 5
NVQOL complete, n = 5
Day 10: eight assessable
PUQE complete, n = 5
NVQOL complete, n = 6
Day 10: seven assessable
PUQE complete, n = 2
NVQOL complete, n = 2
Day 5: eight assessable
PUQE complete, n = 6
Day 5: eight assessable
PUQE complete, n = 7
Day 5: seven assessable
PUQE complete, n = 4
Day 2: eight assessable
PUQE complete, n = 6
Day 2: eight assessable
PUQE complete, n = 7
Day 2: seven assessable
PUQE complete, n = 5
Assessable for primary
outcome, n = 7
20 weeks: six assessable 20 weeks: eight assessable 20 weeks: nine assessable 20 weeks: eight assessable
Assessable for primary
outcome, n = 8
Assessable for primary
outcome, n = 8
Assessable for primary
outcome, n = 7
































Overall, n (%) Pre amendment (before 22 February 2019), n (%) Post amendment (after 22 February 2019)
Screened Eligible Recruited Screened Eligible Recruited Screened Eligible Recruited
Newcastle April 2018 93 26 (28) 5 (19) 60 15 (25) 4 (27) 33 11 (33) 1 (9)
Sunderland May 2018 43 16 (37) 10 (63) 32 9 (28) 8 (89) 11 7 (64) 2 (29)
Leeds May 2018 101 17 (17) 5 (29) 61 13 (21) 5 (38) 40 4 (10) 0 (0)
Bradford June 2018 88 9 (10) 1 (11) 59 6 (10) 0 (0) 29 3 (10) 1 (33)
South Tees June 2018 43 12 (28) 6 (50) 33 4 (12) 1 (25) 10 8 (80) 5 (63)
Birmingham July 2018 64 8 (13) 2 (25) 48 8 (17) 2 (25) 16 0 (0) 0 (NA)
St Thomas’ July 2018 81 26 (32) 4 (15) 20 6 (30) 3 (50) 61 20 (33) 1 (5)
Nottingham March 2019 34 1 (3) 0 (0) NA NA NA 34 1 (3) 0 (0)
Portsmouth May 2019 25 2 (8) 0 (0) NA NA NA 25 2 (8) 0 (0)
St George’s May 2019 16 3 (19) 0 (0) NA NA NA 16 3 (19) 0 (0)
Oldham May 2019 3 2 (67) 0 (0) NA NA NA 3 2 (67) 0 (0)
Stoke July 2019 1 0 (0) 0 (NA) NA NA NA 1 0 (0) 0 (NA)

































































































































































































































































































































Newcastle 67 52 (78) 4 (6) 0 (0) 6 (9) 1 (1) 2 (3) 2 (3) 0 (0) 0 (0)
Sunderland 27 17 (63) 1 (4) 0 (0) 1 (4) 0 (0) 3 (11) 3 (11) 1 (4) 1 (4)
Leeds 84 37 (44) 8 (10) 1 (1) 7 (8) 1 (1) 8 (10) 1 (1) 17 (20) 4 (5)
Bradford 79 62 (78) 8 (10) 2 (3) 1 (1) 0 (0) 3 (4) 3 (4) 0 (0) 0 (0)
South Tees 31 27 (87) 1 (3) 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 1 (3) 0 (0)
Birmingham 56 47 (84) 6 (11) 0 (0) 0 (0) 0 (0) 3 (5) 0 (0) 0 (0) 0 (0)
St Thomas’ 55 26 (47) 5 (9) 2 (4) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 21 (38)
Nottingham 33 27 (82) 1 (3) 0 (0) 1 (3) 0 (0) 2 (6) 2 (6) 0 (0) 0 (0)
Portsmouth 23 14 (61) 0 (0) 1 (4) 1 (4) 0 (0) 2 (9) 0 (0) 4 (17) 1 (4)
St George’s 13 9 (69) 1 (8) 0 (0) 0 (0) 1 (8) 1 (8) 1 (8) 0 (0) 0 (0)
Oldham 1 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Stoke 1 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 470 320 (68) 35 (7) 6 (1) 17 (4) 3 (1) 26 (6) 13 (3) 23 (5) 27 (6)
































(before 22 February 2019)
(N= 128), n (%)
Post-protocol amendment
(after 22 February 2019)
(N= 134), n (%)
Drug given
Ondansetron 215 (83) 107 (84) 108 (82)
First line 62 (36) 18 (26) 44 (43)
Second line 108 (64) 50 (74) 58 (57)
Missing 45 39 6
Metoclopramide 44 (17) 20 (16) 24 (18)
First line 22 (58) 8 (50) 14 (64)
Second line 16 (42) 8 (50) 8 (36)
Missing 6 4 2
Not recorded 3 1 2
Route of administration
Oral only 82 (35) 41 (37) 41 (33)
Taken for ≤ 3 days 12 (23) 10 (48) 2 (6)
Taken for > 3 days 40 (77) 11 (52) 29 (94)
Missing duration 30 20 10
i.v. (± oral treatment) 137 (59) 55 (50) 82 (67)
i.m. or PR 14 (6) 14 (13) 0 (0)
Missing 29 18 11
Source of prescription
GP 57 (24) 28 (25) 29 (24)
Secondary care 179 (76) 86 (75) 93 (76)
A&E department 39 (22) 18 (22) 21 (23)
Gynaecology/early pregnancy clinic 61 (35) 15 (18) 46 (49)
Maternity 75 (43) 49 (60) 26 (28)
Missing 30 18 12
Reason prescribed: if from secondary care
Woman’s request 4 (3) 3 (4) 1 (1)
Doctor’s preference 62 (40) 27 (38) 35 (40)
No research staff available 93 (58) 41 (58) 52 (59)
Attended out of hours 76 (82) 33 (80) 43 (83)
Other reason 17 (18) 8 (20) 9 (17)
Missing 20 15 5
i.m., intramuscular; PR, per rectum.
DOI: 10.3310/hta25630 Health Technology Assessment 2021 Vol. 25 No. 63
Copyright © 2021 Robson et al. This work was produced by Robson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
25
The progression criterion to the main trial was set at 59 participants to be recruited within 6 months,
with ≥ 40 participants retained for data collection at day 10. The trial opened to recruitment on
24 April 2018 and by the end of October 2018 seven sites were open to recruitment, with only
17 participants recruited.
Screening data showed that a larger than anticipated proportion of women were ineligible owing to
prior treatment with ondansetron or metoclopramide in the current pregnancy. Following advice from
the TSC, trial co-applicants, TMG and the HTA programme, the eligibility criteria were broadened in
February 2019 to allow patients who had previously received suboptimal treatment with ondansetron
or metoclopramide (orally for < 72 hours) in their current pregnancy to be included. Women who had
received either of the trial drugs intravenously or orally for > 72 hours (with or without i.v. rehydration)
were still ineligible.
The pilot phase was extended to the end of August 2019. The revised stop–go criterion required
96 participants to be recruited by the end of August 2019. This was based on a recruitment rate of
one participant per site per month, with an additional six sites open to recruitment by May 2019.
Progress was reviewed with the iDMC, TSC and HTA programme in July 2019. At this time,
32 participants had been recruited and five additional sites had been opened. The main reason for
ineligibility continued to be prior treatment with trial drugs, despite the protocol amendment to
broaden the eligibility criteria. It was therefore decided that the trial would close and not progress
to a main trial. Following the closure of the trial to recruitment in August 2019, follow-up of
participants continued until the final pregnancy outcome was reported in April 2020.
Figure 3 shows the cumulative accrual rates originally anticipated for the pilot phase, the revised target
for the pilot phase and the actual recruitment.
Withdrawals and ineligible participants
No participants were found to be ineligible after randomisation.




Reason that eligible participant was not recruited (N = 89)
Declined 62 (70)
Not approached 16 (18)
Not recorded 11 (12)
Reasons that participants declined (N = 62)
Too unwell to consider information 13 (21)
Worried care would be affected (e.g. chance of getting dummy)/does not want dummy 14 (23)
Preference for specific treatment(s)/does not want (trial) drug(s) 12 (19)
Too busy/other commitments/would find it difficult to participate 7 (11)
Does not want to participate in research/sees no benefit in trial 4 (6)
Worried subsequent care would be affected (e.g. would not know what drug received) 1 (2)
No reason given 7 (11)
Other reason 4 (6)
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Two participants withdrew from the trial without allowing any use of routine data; both were allocated
to receive active metoclopramide and dummy ondansetron. One participant withdrew on day 4 for
personal reasons following treatment failure (this participant was evaluable for the primary outcome
given that treatment failure was reported prior to withdrawal). The other participant wished to
withdraw from the trial owing to perceived side effects of the medication on day 2. This participant
was not evaluable for the primary outcome.
A further two participants withdrew from trial treatment and further follow-up assessments but
allowed routine data to be collected (one metoclopramide and ondansetron, and one double dummy).
Both of these participants withdrew prior to receiving 12 hours of trial drugs because they requested
further medications or were not feeling better. Neither of these participants was evaluable for the
primary outcome.
Numbers analysed
Thirty (91%) participants were evaluable for the primary outcome: seven (88%) active metoclopramide
and dummy ondansetron; eight (100%) active ondansetron and dummy metoclopramide; eight (89%)
metoclopramide and ondansetron; and seven (88%) double dummy. For information on those who were
not evaluable for the primary outcome, see Withdrawals and ineligible participants.
Thirty-one (94%) participants were evaluable for data collected on readmissions for NVP and further
antiemetic treatments prescribed up to 20 weeks’ gestation: six (75%) active metoclopramide and
dummy ondansetron; eight (100%) active ondansetron and dummy metoclopramide; nine (100%)
metoclopramide and ondansetron; and eight (100%) double dummy. Those who were not evaluable
were those participants who withdrew from the trial without allowing any use of routine data.
Between 20 weeks and delivery, 28 participants (85%) were evaluable, with three participants
reporting a TOP prior to 20 weeks’ gestation.
Patient-reported outcome measures (PUQE, VAS for nausea, NVPQoL questionnaire, EPDS and
six-item STAI) were expected from 29 (88%) participants at day 10, with four participants (two active
metoclopramide and dummy ondansetron; one metoclopramide and ondansetron; and one double



















































































































FIGURE 3 Cumulative recruitment by month.
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Baseline data
Demographic and clinical baseline characteristics are presented by randomised treatment group in
Table 6. Further baseline demographics, including baseline values of participant-reported outcome
measures, can be found in Appendix 9, Table 18; Appendix 10, Table 19; and Appendix 11, Table 20.
The median gestation at the time of trial entry was 85/7 weeks and ranged from 5 weeks to 162/7 weeks.
Three (9%) women were expecting more than one baby. Overall, 12 (36%) women had not had a previous
pregnancy. Of the 21 women who had had a prior pregnancy, 16 (76%) had experienced NVP in a
previous pregnancy. All of the women had received at least one first-line antiemetic medication, with
26 (79%) receiving cyclizine, 13 (39%) receiving prochlorperazine and five (15%) receiving promethazine.



























27 (18, 34) 34 (21, 38) 27 (21, 38) 24 (18, 32) 27 (18, 38)
Ethnicity
White British, n (%) 6 (75) 6 (75) 8 (89) 6 (75) 26 (79)




76/7 (65/7, 133/7) 86/7 (76/7, 162/7) 76/7 (50/7, 125/7) 94/7 (65/7, 155/7) 85/7 (50/7, 162/7)
Multiple birth, n (%) 1 (13) 1 (13) 1 (11) 0 (0) 3 (9)
First-line medication received,a n (%)
Cyclizine 7 (88) 7 (88) 7 (78) 5 (63) 26 (79)
Promethazine 0 (0) 1 (13) 3 (33) 1 (13) 5 (15)
Prochlorperazine 2 (25) 3 (38) 4 (44) 4 (50) 13 (39)
Gravida, n (%)
1 3 (38) 1 (13) 3 (33) 5 (63) 12 (36)
2 1 (13) 3 (38) 4 (44) 0 (0) 8 (24)
3 2 (25) 0 (0) 1 (11) 0 (0) 3 (9)
4 2 (25) 1 (13) 0 (0) 2 (25) 5 (15)
5–8 0 (0) 3 (38) 1 (11) 1 (13) 5 (15)
Parity, n (%)
0 4 (50) 1 (13) 4 (44) 6 (75) 15 (45)
1 2 (25) 4 (50) 4 (44) 1 (13) 11 (33)
2 2 (25) 0 (0) 0 (0) 1 (13) 3 (9)
3 0 (0) 3 (38) 1 (11) 0 (0) 4 (12)
Past pregnancies 5 (63) 7 (88) 6 (67) 3 (38) 21 (64)
If yes, NVP in any
past pregnancy
3 (60) 6 (86) 6 (100) 1 (33) 16 (76)
a Not mutually exclusive.
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Treatment received
All of the participants received at least one dose of their allocated trial drugs. One participant
(allocated to double dummy) received only oral trial drugs at her request. All of the other participants
received the trial drugs intravenously initially. The number of i.v. doses received is summarised in
Table 7. One participant (allocated to active ondansetron) received three i.v. doses; however, two were
received on day 4 following a readmission to hospital (for reasons other than NVP) and being nil by
mouth (incidental paronychia; see Safety).
Thirteen (39%) participants completed the 10-day trial treatment period; however, one participant
(who was allocated to receive active metoclopramide and active ondansetron) missed 16 doses of
medication (equivalent to 5.3 days of treatment) because of side effects (drowsiness reported as an
AE; see Safety). Fifteen (45%) participants discontinued treatment owing to treatment failure, as per the
primary outcome. The remaining five (15%) participants chose to discontinue treatment prior to day 10.
Two participants chose to discontinue treatment before 12 hours because they were not feeling better
and requested further medications (one active metoclopramide and active ondansetron, and one double
dummy); both received only one i.v. dose of the trial drugs and did not convert to oral medication. One
participant (who was allocated to receive active metoclopramide alone) chose to discontinue treatment
on day 2 owing to side effects (‘funny feeling in legs’, ‘increase in anxiety’ and ‘nightmares’ were reported
as AEs). One participant (who was allocated to receive active metoclopramide and active ondansetron)
chose to discontinue trial treatment on day 2 because she reported feeling better and decided to manage
her symptoms without medication. Another participant (who was allocated to receive double dummy)
chose to discontinue treatment on day 5 because she felt that the medication was not effective, but was
feeling better so did not seek further review.
TABLE 7 Treatment received
Treatment
























Number of i.v. doses
0 0 (0) 0 (0) 0 (0) 1 (13) 1 (3)
1 8 (100) 7 (88) 8 (89) 5 (63) 28 (85)
2 0 (0) 0 (0) 1 (11) 2 (25) 3 (9)
3 0 (0) 1 (13) 0 (0) 0 (0) 1 (3)
Converted to oral
medication
8 (100) 8 (100) 8 (89) 7 (88) 31 (94)
Completed 10-day treatment period
Yes 3 (38) 6 (75) 3 (33) 1 (13) 13 (39)
No: treatment failure 4 (50) 2 (25) 4 (44) 5 (63) 15 (45)
Time until treatment failure (hours)
≤ 48 1 (25) 0 (0) 1 (25) 1 (20) 3 (20)
48.1–120 3 (75) 0 (0) 2 (50) 3 (60) 8 (53)
> 120 0 (0) 2 (100) 1 (25) 1 (20) 4 (27)
No: treatment discontinued
for other reason
1 (13) 0 (0) 2 (22) 2 (25) 5 (15)
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Primary outcome measure
Overall, 30 participants were evaluable for the primary outcome. Of those 30 participants, treatment failure
between 12 hours and 10 days occurred in four (57%) participants allocated to active metoclopramide and
dummy ondansetron, two (25%) participants allocated to active ondansetron and dummy metoclopramide,
four (50%) participants allocated to active metoclopramide and active ondansetron, and five (71%)
participants allocated to double dummy (Table 8). Three participants (one active metoclopramide and
dummy ondansetron, one active metoclopramide and active ondansetron, and one double dummy)
reported treatment failure within the first 48 hours. Further antiemetic treatments received are
summarised in Table 8. One participant (who was allocated to receive active metoclopramide and
dummy ondansetron) did not have information available on further treatments received because she
withdrew from the trial, including the use of any routine data, following treatment failure. Thirteen
(93%) of those participants reporting a treatment failure received oral antiemetics, four (29%) received
i.v. antiemetics and five (36%) received intramuscular antiemetics.
























Number evaluable, n (%) 7 (88) 8 (100) 8 (89) 7 (88) 30 (91)
Treatment failure
between 12 hours and












48 hours, n (%)
1 (14) 0 (0) 1 (13) 1 (14) 3 (10)
Further antiemetic treatment received, n (%)
Ondansetron alone 0 (0) 1 (50) 1 (25) 1 (20) 3 (21)
Cyclizine alone 0 (0) 1 (50) 0 (0) 1 (20) 2 (14)
Metoclopramide alone 0 (0) 0 (0) 0 (0) 1 (20) 1 (7)
Cyclizine and
prochlorperazine
1 (33) 0 (0) 1 (25) 1 (20) 3 (21)
Prochlorperazine and
ondansetron
1 (33) 0 (0) 1 (25) 1 (20) 3 (21)
Cyclizine and
ondansetron
1 (33) 0 (0) 0 (0) 0 (0) 1 (7)
Metoclopramide and
ondansetron
0 (0) 0 (0) 1 (25) 0 (0) 1 (7)
Unknown 1 0 0 0 1
Route(s) of further antiemetic treatment(s), n (%)
Oral 3 (100) 2 (100) 3 (75) 5 (100) 13 (93)
i.v. 1 (33) 1 (50) 0 (0) 2 (40) 4 (29)
i.m. 1 (33) 0 (0) 3 (75) 1 (20) 5 (36)
Unknown 1 0 0 0 1
CI, confidence interval; i.m., intramuscular.
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Secondary outcome measures
Clinical indicators of antiemetic effectiveness
Readmissions [including assessment unit (AU) visits] for NVP up to 20 weeks’ gestation are summarised
in Table 9. Of those evaluable readmissions (n = 31), nine (29%) (including for a day visit) occurred within
the first 10 days. Between day 10 and 20 weeks’ gestation, seven (23%) participants were readmitted: one
allocated to active metoclopramide and dummy ondansetron, three allocated to active ondansetron
and dummy metoclopramide, three allocated to active metoclopramide and active ondansetron, and no
one allocated to double dummy. Between 20 weeks’ gestation and delivery, three participants were
readmitted to hospital for NVP: one allocated to active ondansetron and dummy metoclopramide, and
two allocated to active metoclopramide and active ondansetron.
TABLE 9 Readmissions (including AU visits) for NVP
























Up to 20 weeks’ gestation
Evaluable 6 (75) 8 (100) 9 (100) 8 (100) 31 (94)
Number of readmissions within 10 days
0 4 (67) 6 (75) 5 (56) 7 (88) 22 (71)
1 1 (17) 1 (13) 4 (44) 1 (13) 7 (23)
2 0 (0) 1 (13) 0 (0) 0 (0) 1 (3)
3 1 (17) 0 (0) 0 (0) 0 (0) 1 (3)
Number of readmissions between 10 days and 20 weeks’ gestation
0 5 (83) 5 (63) 6 (67) 8 (100) 24 (77)
1 0 (0) 3 (38) 2 (22) 0 (0) 5 (16)
2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
4 1 (17) 0 (0) 1 (11) 0 (0) 2 (6)
Number of inpatient days between trial entry and 20 weeks’ gestation
0 4 (67) 5 (63) 4 (44) 7 (88) 20 (65)
1 1 (17) 0 (0) 2 (22) 1 (13) 4 (13)
2 0 (0) 1 (13) 2 (22) 0 (0) 3 (10)
3 0 (0) 2 (25) 0 (0) 0 (0) 2 (6)
5 0 (0) 0 (0) 1 (11) 0 (0) 1 (3)
9 1 (17) 0 (0) 0 (0) 0 (0) 1 (3)
20 weeks’ gestation to delivery
Number assessable 6 (75) 7 (88) 8 (89) 7 (88) 28 (85)
continued
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Further antiemetic treatments prescribed up to 20 weeks’ gestation and between 20 weeks’ gestation
and delivery are summarised in Table 10. Up to 20 weeks’ gestation, further antiemetic treatment
was prescribed to 25 (81%) participants: four (67%) allocated to active metoclopramide and dummy
ondansetron, seven (88%) allocated to active ondansetron and dummy metoclopramide, eight (89%)
allocated to active metoclopramide and active ondansetron and six (75%) allocated to double dummy.
Twenty (65%) participants were prescribed ondansetron, 10 (32%) cyclizine, eight (26%) prochlorperazine,
seven (23%) metoclopramide and one (3%) promethazine. Between 20 weeks’ gestation and delivery,
12 (43%) participants received further antiemetic treatment. Further information on relapse and remission
rates, as defined by changes in PUQE score, can be found in Appendix 12, Table 21.
TABLE 9 Readmissions (including AU visits) for NVP (continued )

























0 6 (100) 6 (86) 6 (75) 7 (100) 25 (89)
1 0 (0) 1 (14) 1 (13) 0 (0) 2 (7)
2 0 (0) 0 (0) 1 (13) 0 (0) 1 (4)
Number of inpatient days
0 6 (100) 6 (86) 6 (75) 7 (100) 25 (89)
1 0 (0) 1 (14) 1 (13) 0 (0) 2 (7)
2 0 (0) 0 (0) 1 (13) 0 (0) 1 (4)
TABLE 10 Additional antiemetic use
























Between trial entry and 20 weeks’ gestation
Number assessable 6 (75) 8 (100) 9 (100) 8 (100) 31 (94)
Number of different antiemetics prescribed
0 2 (33) 1 (13) 1 (11) 2 (25) 6 (19)
1 0 (0) 4 (50) 2 (22) 4 (50) 10 (32)
2 2 (33) 3 (38) 4 (44) 2 (25) 11 (35)
3 2 (33) 0 (0) 0 (0) 0 (0) 2 (6)
4 0 (0) 0 (0) 2 (22) 0 (0) 2 (6)
Route of administrationa
Oral 4 (67) 7 (88) 8 (89) 6 (75) 25 (81)
i.v. 2 (33) 1 (13) 1 (11) 2 (25) 6 (19)
i.m. 1 (17) 1 (13) 3 (33) 1 (13) 6 (19)
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Participant-reported outcomes
The number of fully completed participant-reported questionnaires at days 2, 5 and 10 is shown in Table 11.
At day 2, of those evaluable (n= 30), 24 (80%) participants had completed a PUQE questionnaire; by day 5
and day 10 this figure had fallen to 22 (76%) and 15 (52%) of those evaluable (n = 29), respectively.
Of the 15 PUQE questionnaires completed at day 10, three were from participants who had met the
primary outcome of treatment failure, meaning that 12 participants in whom treatment had failed did
not have a completed questionnaire. These figures were similar for other questionnaires (see Table 11).
Summaries of the participant-reported outcome measures at each time point can be found in Appendix 10,
Table 19 and Appendix 11, Table 20.
TABLE 10 Additional antiemetic use (continued )

























Ondansetron 3 (50) 6 (75) 8 (89) 3 (38) 20 (65)
Cyclizine 3 (50) 3 (38) 2 (22) 2 (25) 10 (32)
Prochlorperazine 3 (50) 0 (0) 3 (33) 2 (25) 8 (26)
Metoclopramide 1 (17) 1 (13) 4 (44) 1 (13) 7 (23)
Promethazine 0 (0) 0 (0) 1 (11) 0 (0) 1 (3)
Between 20 weeks’ gestation and delivery
Number assessable 6 (75) 7 (88) 8 (89) 7 (88) 28 (85)
Number of different antiemetics prescribed
0 4 (67) 4 (57) 3 (38) 5 (71) 16 (57)
1 2 (33) 2 (29) 1 (13) 1 (14) 6 (21)
2 0 (0) 1 (14) 3 (38) 0 (0) 4 (14)
3 0 (0) 0 (0) 1 (13) 1 (14) 2 (7)
Route of administrationa
Oral 2 (33) 3 (43) 4 (50) 2 (29) 11 (39)
i.v. 0 (0) 0 (0) 0 (0) 1 (14) 1 (4)
i.m. 0 (0) 1 (14) 2 (25) 1 (14) 4 (14)
Type of antiemetica
Ondansetron 1 (17) 3 (43) 5 (63) 2 (29) 11 (39)
Cyclizine 1 (17) 0 (0) 1 (13) 1 (14) 3 (11)
Prochlorperazine 0 (0) 1 (14) 1 (13) 0 (0) 2 (7)
Metoclopramide 0 (0) 0 (0) 3 (38) 0 (0) 3 (11)
Promethazine 0 (0) 0 (0) 0 (0) 1 (14) 1 (4)
i.m., intramuscular.
a Not mutually exclusive.
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Pregnancy and neonatal outcomes
The pregnancy and neonatal outcomes are summarised descriptively in Table 12. Of those participants
with follow-up data available (n = 31), 28 (90%) participants had a live birth and three (10%) participants
had a TOP prior to 20 weeks’ gestation. One participant, who was allocated to active ondansetron and
dummy metoclopramide, had a TOP because of fetal abnormalities (see Safety) and two participants,
who were allocated to active ondansetron and active metoclopramide and double dummy, had a TOP
for other reasons. The median gestation at delivery was 391/7 weeks and the median birthweight was
3.0 kg. All infants with a 5-minute Appearance, Pulse, Grimace, Activity, Respiration (Apgar) score
available scored ≥ 7. Three infants (triplets born prematurely at 276/7 weeks gestation) did not have an
Apgar score available. One infant, born to a mother who was allocated to receive double dummy, was
reported to have a congenital abnormality at birth.
TABLE 11 Completion of participant-reported outcomes
Time point

























PUQE 6 (86) 6 (75) 7 (88) 5 (71) 24 (80)
VAS 6 (86) 7 (88) 7 (88) 5 (71) 25 (83)
Withdrawn 1 0 1 1 3
Day 5
PUQE 5 (83) 6 (75) 7 (88) 4 (57) 22 (76)
VAS 5 (83) 6 (75) 7 (88) 4 (57) 22 (76)
Withdrawn 2 0 1 1 4
Day 10
PUQE 3 (50) 5 (63) 5 (63) 2 (29) 15 (52)
Treatment failurea 1 0 1 1 3
VAS 3 (50) 5 (63) 5 (63) 2 (29) 15 (52)
Treatment failurea 1 0 1 1 3
NVPQoL questionnaire 3 (50) 4 (50) 5 (63) 2 (29) 14 (48)
Treatment failurea 1 0 1 1 3
EPDS 3 (50) 5 (63) 5 (63) 2 (29) 15 (52)
Treatment failurea 1 0 2 1 4
STAI 3 (50) 5 (63) 6 (75) 2 (29) 16 (55)
Treatment failurea 1 0 2 1 4
Withdrawn 2 0 1 1 4
a Number of participants meeting the primary outcome of treatment failure with questionnaire completed.
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Health economic outcomes
The response rates relating to participant-completed health economic questionnaires are shown in
Table 13. An equal number of the participants (n = 16, 48%) did not complete any part of the health-care
utilisation and CV questionnaires. The pattern of non-response was similar across the four randomised
treatment groups.
The main results of the WTP analysis are shown in Table 14. Overall, 13 participants (39%) provided an
answer stating the maximum amount that they would be willing to pay to improve symptom severity for
a 10-week period. The mean value across all groups was £674, with the double-dummy group reporting
the lowest mean amount (£123). Participants across the other three randomised groups reported similar
mean values. The minimum amount that a participant was willing to pay was £20 (reported by a participant
in the double-dummy group) and the maximum stated amount was £2000 (reported by participants
in the active metoclopramide and active ondansetron group, and the active ondansetron and dummy
metoclopramide group).
























Number assessable, n (%) 6 (75) 8 (100) 9 (100) 8 (100) 31 (94)
Pregnancy outcome, n (%)
Live born 6 (100) 7 (88) 8 (89) 7 (88) 28 (90)
Termination for fetal
abnormalitya
0 (0) 1 (13) 0 (0) 0 (0) 1 (3)
Termination for other
reasons
0 (0) 0 (0) 1 (11) 1 (13) 2 (6)
If live born
Number of infants
1, n (%) 6 (100) 6 (86) 7 (88) 7 (100) 26 (93)
2, n (%) 0 (0) 1 (14) 0 (0) 0 (0) 1 (4)
3, n (%) 0 (0) 0 (0) 1 (13) 0 (0) 1 (4)

















3.1 (2.8, 3.9) 3.6 (2.6, 4.3) 2.8 (1.0, 4.6) 2.6 (1.9, 3.7) 3.0 (1.0, 4.6)
Apgar score at 5 minutes, n (%)
≥ 7 6 (100) 8 (100) 7 (70) 7 (100) 28 (90)
Not available 0 (0) 0 (0) 3 (30) 0 (0) 3 (10)
Congenital abnormalityb 0 (0) 0 (0) 0 (0) 1 (14) 1 (3)
a See Table 15, SAE 003.
b Examination identified an undescended left testis. Antenatal ultrasound had identified an absent left kidney and a
possible duplex right kidney.
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Safety
The three SAEs that were reported during the trial are shown in Table 15. The TOP owing to fetal
abnormalities was classed as a suspected unexpected serious adverse reaction (SUSAR), as the
participant was identified as having received ondansetron following emergency unblinding. The
causality of the event was indeterminable in relation to the IMP (ondansetron) and unexpected.
The SUSAR underwent expedited reporting to the MHRA and REC and all site PIs were informed
of the event.
Three further events, in two participants, were reported as being possibly related to trial treatment: one
participant allocated to active metoclopramide and dummy ondansetron reported both constipation and
diarrhoea; and one participant allocated to active metoclopramide and active ondansetron reported
drowsiness. None of these events was serious.
TABLE 13 Completion of health economic questionnaires
Completion



























3 (37) 5 (63) 6 (67) 3 (37) 17 (52)
Not completing any
part of the health-care
utilisation questionnaire




3 (37) 5 (63) 6 (67) 3 (37) 17 (52)
Not completing any
part of the CV
questionnaire
5 (63) 3 (37) 3 (33) 5 (63) 16 (48)
























Mean (SD) 725 (742) 740 (796) 833 (1012) 123 (117) 617 (715)
Median (IQR) 725 (200–1250) 500 (100–1000) 300 (200–2000) 100 (20–250) 250 (100–1000)
Maximum WTP value 1250 2000 2000 250 2000
Minimum WTP value 200 100 200 20 20
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Urgent safety measure
Immediately following the decision to close the extended internal pilot trial owing to recruitment
challenges, the European Medicines Agency (EMA)’s Pharmacovigilance Risk Assessment Unit informed
the trial of an urgent safety measure relating to ondansetron, recommending that it should not be used
during the first trimester of pregnancy. Owing to the imminent closure of the trial, the urgent safety
measure was implemented and recruitment to the pilot closed. All participants receiving trial medication
were informed to discontinue their trial medication with immediate effect. Participants continued to be
followed up until birth outcome. Following discussion with the TSC, the decision was subsequently taken
to unblind all participants and inform them of the medication that they had received.
TABLE 15 Reported SAEs, SARs or SUSARs
SAE ID Treatment group Event description Severity Type of event
001 Active metoclopramide
and dummy ondansetron
Right calf deep-vein thrombosis Moderate SAE
002 Active ondansetron and
dummy metoclopramide
Incidental paronychia Mild SAE
003 Active ondansetron and
dummy metoclopramide
Termination of pregnancy owing
to fetal abnormalitiesa
Severe SUSAR
a Ultrasound at 155/7 weeks’ gestation identified a small-for-gestational age fetus with neck (cystic hygroma), brain
(ventriculomegaly and abnormal cerebellar shape) and cardiac (aberrant right subclavian artery and tricuspid
regurgitation) anomalies. Post-mortem examination (following TOP at 16+3 weeks’ gestation) showed facial
dysmorphic features (hypertelorism, long philtrum, low-set and posteriorly rotated ears) and aberrant right
subclavian artery. The brain could not be examined owing to disruption. Genetic analysis showed a normal male
chromosome compliment with no significant (> 0.4Mb) imbalance. Following a subsequent pregnancy, also
complicated by multiple fetal abnormalities, a mitochondrial gene mutation was identified.
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Chapter 4 Qualitative substudy: hurdles
to and enablers of the EMPOWER trial
A total of 42 EOI forms (from 34% of all eligible women) were received. Between May 2018 andAugust 2019, 21 of the 42 women (50%) were interviewed, of whom seven (33%) had declined
participation in the trial (Table 16). Most of the 21 women who were not interviewed did not respond
to the researcher’s follow-up contact (between 14 and 28 days after the initial contact) despite their
initial EOI. Two women agreed to be interviewed but did not respond subsequently, and two women
declined to be interviewed when contacted. Seven women were interviewed after the protocol
amendment. Ten out of the 21 patient participants were interviewed over the telephone at their
first point of contact, and seven interviews took place at an arranged time following the initial contact.
Four women completed the interview through an exchange of e-mails. The telephone interviews lasted
a median of 8.2 (range 5.4–16.2) minutes.
Most of the clinicians who were contacted were willing to participate; 22 research staff (research
midwives or nurses, n = 16; PIs, n = 6) were interviewed between December 2018 and September 2019.
The majority of clinicians (n = 16) were interviewed after the protocol was amended to broaden the
eligibility criteria. Six of these interviews were conducted with site PIs towards the end of recruitment
to the qualitative study. The telephone interviews with research staff lasted a median of 24.3
(range 12.1–44.5) minutes.
Altogether, 72 codes were generated from the NVivo12 coding, of which 36 nodes related to the
patient interviews and 36 to research staff. The findings from these codes formed the framework
describing the hurdles to and enablers of the process of conducting trial recruitment (see Appendix 13,
Tables 22 and 23). These are presented under three headings: (1) requirements of the EMPOWER
Clinical Trial of an Investigational Medicinal Product (CTIMP) in the context of the RCOG guidelines;12
(2) the presenting patient and pathways to care and to trial recruitment; and (3) the role of research
staff. The key themes and subthemes are summarised in Figure 4.
Requirements of the EMPOWER trial (theme 1)
When staff were asked how the EMPOWER trial compared with other trials that they had worked on,
the complexity of the trial was a recurrent theme in many responses. The TMG were aware of the
TABLE 16 Interview trial participants and non-participants
Site EOIs (n) Acceptors (n) Decliners (n) Interviewed (n) Acceptors (n) Decliners (n)
Newcastle 9 4 5 4 2 2
Sunderland 10 9 1 4 4 0
Leeds 6 3 3 2 1 1
Birmingham 3 1 2 2 0 2
London 4 4 0 4 4 0
Bradford 5 1 4 2 0 2
South Tees 4 4 0 3 3 0
Portsmouth 1 0 1 0 0 0
Total 42 26 16 21 14 7
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trial’s complexities and attempted to take account of them in the trial design and site selection (i.e. the
initial sites for the internal pilot were chosen because the research staff at the site had experience of
recruiting pregnant women into CTIMPs). However, the demands of the CTIMP had a variable effect
on recruitment across sites.
The trial question and adherence to the Royal College of Obstetricians and
Gynaecologists guidelines
For the trial to succeed as intended, the rationale for the research needed to be understood and
accepted by all those involved in delivering the trial. As the trial progressed, however, two emerging
Theme 1: requirements of the EMPOWER trial
Theme 2: presentation of women to maternity services
Infrequency
Theme 3: trial staff roles
Unpredictability
The study question and adherence to
RCOG guidelines12
Organising the delivery of the
EMPOWER trial
Demands of the EMPOWER
trial protocol
Publicity and education about the trial:
primary care and A&E departments
Women who were ineligible
Treatment with i.v. fluids and
first-line antiemetic treatment
Previous prescription of study drugsLanguage difficulties
Women who were eligible
The risk of the condition not improving 
The impact of severe NVP on trial
participation






Use of concomitant medications
Perceived research burden
Staffing levels and supportPatient counselling and staff empathy
Recruitment and trial processesConfidence and morale
FIGURE 4 Summary of the themes in the qualitative evaluation.
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issues were identified by some site PIs: first, that the trial question had lost its relevance and second,
that NVP had a lower priority than other pregnancy complications:
. . . if I’m honest with you I think the general feeling was that practice has moved on, and that the
question that this trial was asking was now probably a historical question . . . You know we’d almost like
we’d missed the boat.
TS19
. . . when we’re coming to nausea and vomiting the perceived, the sort of the perceived issues or problems
coming out of it will not sort of rank alongside stillbirth or neonatal death.
TS18
However, other PIs, patients and midwives/nurses were of the opinion that research in this area was
much needed and that the trial question remained important. This was in spite of the issue of
randomisation to double dummy being controversial at the initial stages among patient and public
involvement advisors:
I thought it was a well-designed study and it was worth definitely worth, a question worth asking . . .
I don’t think the study design was a problem which was what we initially thought was going to be
a problem.
TS18
There was evidence from both PIs and research midwives/nurses that there had been a change in the
practice of prescribing antiemetic drugs since the decision was made to conduct the trial (February 2016),
which impacted negatively on recruitment during the course of the trial:
I think because it took us a long while to get it going and I think the whole landscape changed almost just
before we started recruiting [. . .] and my, my belief is that was largely to do with the guideline the RCOG
guideline . . . the trial was an independent endeavour but meanwhile there were lots of us working in the
background to improve care for women with hyperemesis, which meant enabling GPs and hospital doctors
to prescribe appropriately for it, and ironically our success in doing that has led to the failure of the trial.
TS16
This shift in practice was evident in both primary and secondary care in spite of RCOG step-up
guidelines12 recommending the use of the trial drugs as a second-line medication and confirmation
from all trial sites that local guidelines on antiemetic use were consistent with RCOG guidelines.12
However, participants indicated that not all clinicians at the study sites and in general practices in their
localities adhered to these guidelines when they were treating women with severe NVP because they
had become used to prescribing the trial drugs:
It was not easy a trial to start with because of all the bad practice which is all very well set where people
would prescribe whatever antiemetic they would feel like at that time rather than follow RCOG
standardised step-up protocol.
TS17
Some of the research staff at sites were unaware of the antiemetic-prescribing culture within which
the trial was attempting to operate:
. . . we just hadn’t realised how many women were already on those study medications from GPs and
things so it’s been a big eye opener to us about what kind of prescribing practices are out in primary care.
TS20
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As a result of this culture of prescribing in primary and secondary care, women were frequently
presenting with severe NVP having already been treated with one of the trial drugs, rendering them
ineligible for the trial. In some regions, this practice was widespread among GPs, whereas in others the
problem was in secondary care:
I did think initially when the trial started that a lot will be ineligible because the GPs prescribing. But I
was surprised actually we could catch a lot who were eligible and it was, we were messing up their
eligibility at secondary care level which was sorted later part. So I don’t think GPs were a major
problem here.
TS17
Organising the delivery of the EMPOWER trial
The successful delivery of the trial required organisational co-operation from clinical staff across
departments, that is liaison between maternity/obstetrics, gynaecology, emergency and pharmacy
departments. Staff at one trial site were more familiar with trials that were based solely in maternity
services, which meant additional effort working with gynaecology colleagues:
This trial was a little bit different in that it was more gynae[cology] than obstetrics which gave I think the
trial team in every unit a little bit of challenge whereas we’re used to approaching women in pregnancy
further on in pregnancy.
TS16
Nevertheless, there was evidence of good working relationships between clinical staff in maternity and
clinical staff in gynaecology day units, and research staff, to facilitate recruitment:
We work with quite closely with the early pregnancy unit and also gynae[cology] emergency, and what we
decided to do was get the clerical staff that work on reception to contact us, bleep us when the women
were coming in. Cos we’ve got quite a good relationship with that area.
TS21
Where there were staff with both a clinical and a research role, this facilitated the recruitment process
for the EMPOWER trial:
One of our research nurses works there in her substantive role as well. So she does some research and
some early pregnancy and, so that’s brilliant because she knows all the systems she knows all the staff
and consequently they’ve got to know us as well through her. We do, they are very good at referring
people to us.
TS02
In some sites, the responsibility for the care of the patient was restricted to unit or ward staff, with
research staff providing a minimal amount of help. This may be because the number of research staff
was limited. In other sites, however, research staff contributed to the care of eligible women while
they were considering the trial:
. . . what I’ve tended to do is not just give the information sheet and come away but I’ve usually kind of
helped with starting i.v. fluids and you know making sure that if the patient has any questions that
I’m there to answer, you know.
TS04
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Good working relationships with the NCTU staff at Newcastle University were critical to the
operational delivery of the trial. In the initial stages, there were several glitches, mainly to do with the
unavailability of trial staff when they were urgently required:
. . . we’ve tried to call the EMPOWER office and there’s never been anybody who actually works on the
trial available to talk to us.
TS05
. . . you’re usually be able to ring by phone if not but there was no back-up there was no way of getting a
hold of anybody so we just had to scrap it which is not, not great.
TS20
Some staff commented that the trial database was not user-friendly and that it was unhelpful having
separate log-ins to recruit and randomise women:
. . . the whole recruitment process and the databases, having separate databases for randomisation and
things like that it can be very confusing.
TS08
Nevertheless, as the trial progressed, and as lines of communication were more firmly established, sites
reported how helpful the NCTU staff were in supporting the management of the trial:
Yeah we’ve never had a problem we’re in contact regularly we get a lot of e-mails from them if there’s
anything on the database that we haven’t done right, or if there’s any discrepancies they’re quite good at
liaising with us and managing like that, so yeah all our contact with the team has been really positive,
I think it’s a lovely trials team to work with.
TS11
Demands of the EMPOWER trial protocol
The trial protocol stipulated that women had to have taken first-line antiemetic treatment for a
minimum of 24 hours before they could be considered eligible for the trial. Most site guidelines for the
management of NVP did not recommend the admission of women, especially with moderate symptoms,
who were started on first-line antiemetic therapy. Thus, trial staff reported that they were unable to
easily determine if potentially eligible women responded to first-line treatment:
It’s, like we’ve got to get her in and out we can’t wait 3 hours and then see how she feels and then put
her in EMPOWER because they don’t tend to like admitting them either.
TS03
So if they’ve never had anything before, usually in that time they’ll just have one dose of cyclizine and
then go home. So it’s then waiting to see if they come back and then we can consider them.
TS05
Women could return at any time, including out of hours or at the weekend, when site research staff
were not available. Nevertheless, sites were informed that women could be approached about future
consideration of the trial when they were on first-line treatment. This advice was followed at some but
not all sites:
We’ve also seen a few people who have come in and maybe just having their first-line treatment and just
mentioned the study to them and just said we have a study running in the unit you wouldn’t be eligible
for it now but bear it in mind if this treatment doesn’t work for you we may come and see you again.
So just to raise a bit of awareness with these women who might be coming in.
TS13
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One patient suggested that information should be provided about the trial at her first visit to the MAU:
I didn’t know whether you could like send something out after I’d been there in the first time, to say if you
come back there is a trial. So I would have had prior knowledge.
EMP1003
The trial was perceived to be particularly challenging because it was a CTIMP with a complex design
consisting of four groups, as well as requiring a trial population of pregnant women in a fragile
physical and emotional state at the point of recruitment. For this reason, research staff were
required to adopt a sensitive approach and give eligible women enough time (1 hour) to consider
the trial information.
Women’s perspectives provided insight to the recruitment processes. Although one patient felt that
she needed more time to think over her decision to participate, another patient declined because she
thought that her wait for treatment would be lengthened because of the trial:
I think how it was explained was that obviously she would come back with, like in an hour, and then
there was paperwork to be filled out so obviously that took, would have taken time and then that had to
be uploaded in to the computer system to decide which treatment I would then go ahead with . . . I mean
I think we’d had a chat about it so we’d pretty much made our mind up probably what 15 minutes after
she’d left us. So had she maybe been around a little bit sooner than the hour that we were expecting,
that might have helped a little bit.
EMP1003
Research staff reported that they felt that the recruitment process could be quite quick once women
had agreed, whereas approaching the women and making sure that the information was understood
took longer:
. . . obviously going to the patient making sure that they’re eligible, giving them the information sheet
and obviously you want them to have the information sheet for the length of time so that they’re
happy, that they understand and that I understand or know that they understand what we’re asking
of them.
TS04
Some participants reported difficulties in accessing medical staff who were GCP trained. One group
highlighted were GP trainees who were perceived to have less interest either in the specialty area or
in contributing to the research:
I found I was quite successful with the doctors who were career trainees in obs[tetrics] and gynae[cology]
but I didn’t have as much success with the GP trainees because they were here for 4 months or 6 months
and I didn’t find that, they didn’t feel that for the time that it took that it was useful for their CVs.
TS19
On the other hand, other PIs reported that they had ensured that there were enough GCP-trained
doctors available:
So most of our senior trainees have completed the GCP training and they are on the delegation log for a
number of research trials.
TS22
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If women agreed to participate in the trial, the protocol stated that an assessment of treatment
efficacy had to be made at 12 hours to see if they were responding. However, some women felt that
this time period was too long a time to endure:
I mean I do reassure them by saying after 12 hours if the medication wasn’t working you’d be withdrawn
from the study and [ML – yeah] but I guess, you know, for the women who are feeling really bad,
12 hours probably seems like a very long time.
TS01
An additional issue was the chance that participants might receive the double dummy for 12 hours,
an issue highlighted by both site staff and prospective participants:
And if they come in when they’re really, really ill when they come in, I could sort of see people not
wanting to do that really just risking getting the placebo.
TS15
. . . I was really, really worried that I had two placebos.
EMP1702
The need for double blinding meant that participants were not aware of the trial drugs that they were
taking. Concerns about unblinding in the event of treatment failure or trial withdrawal were dealt with
through the initiatives of the research teams (e.g. by prescription of both trial drugs). However, this did
not take away the desire of some participants to know what medication they had received after the
trial was completed:
I just think sort of ethically I would although you sign up to do a trial you do have a right to know what
you took because now I’m guessing I was on metoclopramide so in a way, or you know guessing that’s the
best one for me to take erm yeah I would, I would like to know what I took.
EMP1702
Publicity and education about the trial
For the trial to be successful, relevant health-care professionals had to be made aware of the
requirements of the trial so that appropriate referrals were made. Medical staff also had to be trained
to approach patients, confirm eligibility, take written consent from the patients and prescribe the trial
drugs. In addition, women with severe NVP needed to be made aware that there was an option for
them to join a trial that might benefit them and other women with the same condition. If health-care
professionals were not offering information about the trial and/or were not adhering to RCOG
guidelines12 on antiemetic use, this could preclude potentially eligible women from participating in the
EMPOWER trial.
Primary care and accident and emergency
Some attempts were made to publicise the trial in primary care by site investigators through local
networks, but participants’ accounts suggested that the effect was felt to be minimal. However, at least
one patient was referred from a GP who knew about the trial:
We also had some communication go out in a GP newsletter, we did get one GP phone us with a lady’s
details who was interested in the trial so we’ve had one referral that way also.
TS02
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Some sites engaged the help of community midwives to communicate information about the trial.
However, for units who provided care for women outside their normal catchment area, this posed
difficulties. For some sites, the proportion of patients in the ‘out-of-area’ category was significant:
. . . we have eight staff, well 7000 women have their babies here every year and half of the women are
what we call ‘out of area’, they’re not our community midwives that look after them.
TS15
The task of publicising the trial and maintaining awareness of the trial was challenging, particularly
in relation to the primary care setting, which involved many doctors working with many competing
priorities:
You know if you’re going to go round and educate all the GPs in [site], they would have quite likely
listened to it and then forgotten about it the next day, you know.
TS18
Accident and emergency department staff also needed to be made aware of the trial; however, this
could be difficult if A&E departments were on a different site or part of a different health-care trust
altogether. In some sites, research staff reported that the number of eligible women being seen in
A&E departments was minimal. Research staff also reported that their A&E departments had a high
turnover of staff and were extremely busy. Furthermore, many lacked dedicated research staff to
remind colleagues about the EMPOWER trial:
A&E, it’s just very difficult because they have like quite a high turnover of staff and they’re a lot more
busy with lots of other stuff.
TS13
But we don’t really have an active research team in our A&E department so it’s not something that A&E
are used to really doing.
TS20
Some research staff made special efforts to liaise with staff in A&E departments, which had some
positive effects. For example, at one site these efforts resulted in a new care pathway for women with
NVP attending the A&E department:
A&E is also very good, we had an exchange of e-mails, we had written the pathways when they have to
refer to us rather than give the antiemetic.
TS17
Clinical and non-clinical staff
Getting clinical staff on board was critical for the EMPOWER trial. However, there were participants
who reported that there were some categories of staff who were less likely to be engaged with
research, such as locums:
So you’re reliant on different doctors coming in, sometimes they’re locums in a very busy unit, haven’t
been able to even think about, is there any research studies that these people might be eligible to.
TS02
Therefore, some staff were not as helpful in supporting recruitment to the trial as they might have
been, especially if they were not part of the regular team. On the other hand, there were also accounts
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of good co-operation from clinical colleagues, which could have been a result of the constant reminders
and training sessions provided by site research staff:
I think it just depends on the individual, like I say, some of them are really good and it’s there in their
mind because they’ve got an interest in it.
TS01
So we did training sessions with the early pregnancy unit staff – they were regular sessions so I did,
I started a couple but then the research nurse did regular training and kind of refresher update sessions
as well.
TS19
Another way that clinical colleagues were supported to engage in the process was through existing
networks and goodwill fostered between staff, including non-clinical staff:
I’ve got the help of somebody who’s looking for the patient and keeping a note of them for me. One of
the, one of the clerks, the ward clerk is actually starting to look each day so hopefully I’ll track them a
little bit better.
TS04
Research staff had to regularly remind colleagues about the EMPOWER trial, otherwise the profile of
the trial among both clinical and non-clinical staff could be lost:
. . . where our offices are, is quite far away from the early pregnancy unit so I make sure I go over at least
kind of once in the morning and once in the afternoon but then I do ring up as well quite regularly and just
say have you got anybody and like I say they’ve got my telephone number written all over the department.
TS05
Research staff accounts indicated that the research culture at the trial sites was also important, but
that there was always the odd clinician unaware of or not alert to the trial protocol:
So it’s, I mean the doctors are aware of the study but it’s just timing and things like that . . . And then you
might get a doctor who for some reason doesn’t know about the study, so.
TS01
Even if all of the requirements of the clinical trial, including the need for publicity and education
among staff, were in place, there was still the issue of patients, their pathway into care and their
attitudes and preferences in relation to the trial.
Presentation of women to maternity services (theme 2)
There were multiple care pathways (Figure 5) that women with severe NVP could take depending on,
for example, their gestation, their history of NVP and their knowledge of how to access care relevant
to NVP. Two key points along the care pathways at which women could receive antiemetic drugs
were at their GP surgery or at an A&E department (see Figure 5). Even with access to dedicated MAUs
or gynaecological assessment units (GAUs), women could be given trial drugs because many of these
units are closed out of hours. Furthermore, although some units had longer opening or weekend hours,
staff working out of hours were unaware of the trial or research teams were not available.
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The impact of the unpredictability of presentation to secondary care
From staff accounts, there did not seem to be predictable patterns of when patients presented to
sites at which recruitment would take place. Women could present with symptoms out of hours, at
weekends or on bank holidays, perhaps because they could not find the time during the week when
they were at work or they had other family commitments. Women might also have to wait until
evening for transport to the hospital by their partners who are at work:
. . . if they’re at home and then someone else brings them cos they’ve been at work all day and then they’ll
bring them in the evening.
TS13
Women who attended at the weekend as an emergency were often given a weekday follow-up
appointment at a specialist MAU or GAU (TS16). Some staff interviewees made reference to the
maternity assessment centre (MAC) or the antenatal day unit, whereas others referred to the early
pregnancy unit or the early pregnancy assessment unit.
In addition, care pathways differed from hospital to hospital depending on the gestational age at
presentation. This influenced when women were referred to specialist assessment units (AUs) at which
they could be approached by trial staff. At some sites, to ease the workload at their MAU, women at
lower gestations were seen within the gynaecology department (either in an early pregnancy unit or
on the gynaecological ward). This meant that research staff had to try to adapt their recruitment
strategies accordingly:
I think it depends on the way that your trust is set up so we, we have the obs[tetrics] med team and they
go and see the ward every single day to see if anyone’s been admitted with hyperemesis.
TS08
In some units, it worked well that the local A&E department policy was to transfer patients with
NVP directly to the specialist MAU or GAU. Some sites provided out-of-hours or 24-hour access to
Pathways and 
referrals
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FIGURE 5 Care pathways of the EMPOWER trial patients. MAUs include maternity assessment centres, MAUs
and antenatal day units. GAUs include early pregnancy units, early pregnancy assessment units, GAUs and gynaecology
day units.
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specialist assessment, but several staff made reference to the issue of women presenting out of hours
leading to their inability to recruit:
But it just, it’s out of hours you know they tend to come in, I think they battle on through the day and
come in on an evening or a weekend or maybe they’ve battled on at work and they they’ve come in out
of hours then, you know, so. But it’s like all trials you’re going to miss you cannot be there 24 hours a day,
7 days a week, so it’s hard.
TS09
However, there were also pathways in which women were encouraged to attend in the daytime if they
were able:
But we have a system where, doesn’t always happen but if somebody’s got hyperemesis and they’re not
too unwell I think certainly from evenings onwards and overnight the appointment is made for them to
come in the morning and they can have their treatment in daylight hours and they can speak to the
research midwives.
TS15
On the other hand, some women presented with such severe symptoms that they were admitted as
inpatients rather than being seen in an AU, which meant that they could potentially be missed by
research staff if they focused efforts on screening women referred to the AU. When the protocol
was changed to allow trial drugs to be taken orally, inpatients treated intravenously were likely to
be missed:
I think once they’ve got to the point where they’ve being admitted to hospital and they’re in and they’re
vomiting and they’re being rehydrated they’ve got i.v. access so they tend to get given i.v. drugs.
TS20
The impact of the infrequency of eligible women
Clinicians reported that the number of women who required specialist assessment and treatment for
severe NVP was small. Familiarity with trial processes took some time to achieve, and research staff
commented that the small number of eligible cases meant that they gained limited experience with the
recruitment processes:
And I think the relatively infrequent presentation of women requiring treatment for nausea and vomiting
in early pregnancy again makes it quite challenging . . . And I think that made it difficult for people to,
for the clinical staff to always be on the ground, and always be on the ball if you like.
TS18
. . . it’s not like you can find your stride very quickly it takes, and then by the time you get another recruit
you think what am I supposed to do again.
TS05
However, to some extent, features of help-seeking in the affected population offset this barrier. For
example, some women attended the site several times, and staff reported that this gave opportunities
for research staff to introduce the trial to them:
Yes to like attend you know the antenatal day unit because for 2 weeks I was constantly going in every
other day because my, my, I was being dehydrated so nothing was working, sickness was at very peak.
Then I kept going in to have some fluids because I was, my ketones in the urine was really high.
EMP1402
DOI: 10.3310/hta25630 Health Technology Assessment 2021 Vol. 25 No. 63
Copyright © 2021 Robson et al. This work was produced by Robson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
49
Women who were ineligible
Treatment with intravenous fluids and first-line treatment
Some patients who declined participation were clear that they wanted to try i.v. fluids first before
considering the trial:
I did say that before erm she told me more about the study that I did say that if I tried the fluids and
then if that didn’t work, I’d try this one.
EMP1501
Staff reported that several women improved considerably with hydration and had not required
antiemetics, making them ineligible for the trial:
I think most women generally responded to the initial management of intravenous hydration itself.
TS22
However, there were women who were aware that hydration could fail and were appreciative of
further options:
. . . it’s nice that people are looking into it more because this is like my second pregnancy and there
wasn’t, my last pregnancy the drip and the normal process didn’t help but this time it did.
EMP1501
At times, staff were unable to recruit women not because they had not received first-line antiemetic
treatment, but because they had not received it for long enough:
. . . that was one of the issues with the study that a lot of women either weren’t given the designated
amount of time or we were seeing them before they’d had the actual amount of time they needed to be
on the first-line treatment.
TS21
Previous prescription of trial drugs
There were women who reportedly would have been very willing to participate in the trial, except that
they had already been treated with a trial drug. These may have been prescribed by the GP or in an
A&E department:
I spoke to a lady the other day and she would have been interested in doing the trial but she’d had one of
the study drugs . . . we’ve had quite a few of those.
TS02
A strong preference and confidence in a particular antiemetic drug was another reason for some
women having received a trial drug.
When the first-line treatment was not effective, clinical staff on duty out of hours had little choice but
to prescribe a trial drug, outside the trial, to women if research staff were not available to conduct the
trial recruitment process there and then:
. . . obviously if you’ve weekends or bank holidays that’s not covered. So if it’s not working there’s no
alternative but to give the metoclopramide or the ondansetron.
TS12
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The protocol amendment allowed women to be considered if they had only received the study drugs
orally. However, many women had been given study drugs intravenously because of the severity of
their symptoms.
TS20
Use of concomitant medications
Some research staff accounts highlighted the concomitant use of other medications, in particular
antidepressants, which rendered a number of women ineligible for recruitment to the trial:
I did a couple of ladies that weren’t eligible due to the fact that they were on certain antidepressant
medication. I did sort of have a chat with them and say, would you, if you had been eligible would you
have been willing to help and the two that I did ask did say yes they would.
TS21
However, one PI commented that this was a very unusual reason for ineligibility at his site, again
indicating variability across sites:
So in the last 9 years I’ve only really come across, no two women who had mental health issues and were
on some kind of antidepressants. So I don’t, it doesn’t feel like that was an issue.
TS19
Language difficulties
Staff from three sites reported that there were issues with women who had insufficient understanding
of the English language to be able to be considered:
Yeah we’ve, I’ve had a few ladies that don’t speak English so we’ve kind of, which is a shame really we’ve
not really been able to, speak to them as well.
TS05
However, for another site, language difficulties did not appear to pose a hurdle for the trial staff:
. . . generally it does not feel to me that ethnicity or language barriers have caused any problems for us.
We’ve had a real mix of ethnicities that have been eligible for us.
TS06
Women who were eligible
The risk of the condition not improving
Women who experienced an improvement in their symptoms with an antiemetic in a previous pregnancy
reported preferring to be on the same medication again, rather than taking the risk of not improving
on the trial drugs:
. . . at the time you just sort of want the treatment, that had been recommended already rather than
messing with and taking things out or, you know replacing it with a placebo and things like that. So I was
more worried about it not working and getting any more ill than I already was because I was really,
really ill.
EMP1502
According to some staff participants, patients were not reassured by the fact that they would receive
i.v. fluids and were discouraged from participating in the trial because of the chance of receiving the
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double dummy. Some women resisted medication but reached a stage at which they were desperate
for their symptoms to be alleviated:
People have been quite put off by the possibility of having a double placebo – that’s the only thing, even
saying that they’ll still be getting fluids it’s just putting people off because I think they’re just, by the time
they come to us.
TS05
However, this patient went ahead with participation despite being quite concerned:
Yeah, I mean yeah it’s worrying because you obviously, you’re obviously at sort of rock bottom, so you do
need to take, you do feel that you need something.
EMP1702
Women who did not have a preference for a particular antiemetic drug were persuaded by a possible
good outcome and the assurance that they could leave the trial at any time:
. . . obviously if it had been prescribed and they think it’s safe for me to take, then I’m going to take it if
it’s going to make me better . . . obviously the midwife was like, the midwife was reassuring me that
everything was going to be OK. So I was like, ‘OK then well let’s do it’.
EMP1202
I was aware I could withdraw if I still hadn’t improved which was very reassuring.
EMP1002
The impact of severe nausea and vomiting in pregnancy on trial participation
All of the sample groups were consistent in their views that the effects of severe NVP had a negative
impact on trial participation. Women who declined felt that it was too much of a burden to try
to deal with research paperwork. Staff corroborated this in their experience of recruiting patients:
Yeah I think at that time I was feeling like, I felt like I couldn’t do any extra than I am already doing.
My condition hyperemesis is quite bad.
EMP1402
. . . the one lady that I had spoken too she just felt too poorly, I mean she was reading the information but
half-way through she sort of like I just feel too unwell . . .
TS14
Research staff who were interviewed expressed concern that the process of trying to screen and
recruit women could have an adverse effect on those they approached:
I think it’s hard sometimes approaching them cos they look how they feel, awful, you know. And
sometimes you just feel like as if you’re hassling them, you know.
TS09
On the other hand, some women were motivated to join the trial to find a solution and for the good of
other women as well:
I feel like there isn’t very much education or things to read about hyperemesis and I actually thought I
want to do something that does inform other women because I just didn’t want anyone to go through er
what I had, er you know I hope in the future.
EMP1702
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Some staff noted that even women suffering from severe NVP were nevertheless still keen to
participate:
I can’t imagine how women fill in these questionnaires and even focus on them but they’re very generous
and they say if we can do anything to help people stop feeling as bad as we do then, that’s what they’ve
all said, if this will help, to not feel as bad as I do then I’m happy to do it.
TS02
Reading and understanding the information
At least two women admitted that they could not be sure that they took in all of the information
because of the way that they were feeling:
Some, some of the information was making sense but obviously some wasn’t because at this point I was
still being sick.
EMP1104
I’d been struggling to concentrate at work and in life, so I think the one pager was quite good and the
second page I looked at, at a later point. I did look at it in the hospital, but I don’t know how much
information I actually processed.
EMP1702
This was corroborated by trial staff, who reported women rejecting the literature because they were
too sick to read it:
Like a couple of women that I’ve had are like ‘d’you know, I can’t even read that leaflet that you’re asking
me to read’. They’re curled up on the bed in a ball, being sick into a bowl next to them, they don’t want to
look at anyone they don’t want to talk to anyone.
TS03
However, sickness was not always an unsurmountable barrier; some women commented that they
received help going through the information, either from the research staff or from those who
accompanied them to hospital:
. . . even though I was feeling really awful they were very good at going through the consent form and
sheets with me and luckily I had a partner there who was able to read the sheets and sort of condense it
down for me [. . .] make sure I knew what was going on.
EMP1703
So I had to get the, get my friend to read everything out so I understood everything. So that’s how we did
it and that’s how we did all the interviews and how we managed to start the information for the trial.
EMP1704
. . . my mum was just sat there and did the paperwork ’cos I couldn’t do it.
EMP1103
Research staff reported that the flow chart provided by the TMG assisted understanding:
The pictorial, you know the flow chart diagram is particularly useful when it comes to trying to explain to
women what the different treatment arms are cos I think they often understand it when they sort of see
it as a diagram, you know they might get selected for one or both or none.
TS07
DOI: 10.3310/hta25630 Health Technology Assessment 2021 Vol. 25 No. 63
Copyright © 2021 Robson et al. This work was produced by Robson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
53
This information aid thus helped women to provide informed consent for the trial. When asked about
their experience, one staff member described how they felt that the information could be made more
accessible to sick patients:
There is a trial manager for a gynaecology trial and they did that they got somebody to read their patient
information leaflet on a YouTube [YouTube, LLC, San Bruno, CA, USA] video and then they used to give
out iPads [Apple Inc., Cupertino, CA, USA] and get them to watch it [ML – amazing] rather than them
having to sit and read. Which yeah it doesn’t take long and once you’ve done it you don’t need to do it
again do you so that was something they found really helpful.
TS20
Although the large amount of information to take in during the recruitment process could be a factor
in discouraging participation, one woman said that she was persuaded by the information that she read
to join the trial:
I just read the leaflet with all the information and then . . . it kind of persuaded me . . . When I was
reading it I just felt like I could make, help other people and feel better myself with it.
EMP1701
Needing a quick, effective solution
Women with severe NVP were desperate for their condition to improve. Any delay in treatment that
might improve symptoms discouraged women from joining the trial, a point also recognised by site
staff. This was especially the case if they had children to take care of or work to get back to:
. . . the only reason I didn’t do the clinical trial was because I was going home after 8 hours, and I’ve got a
little girl at home.
EMP1001
. . . because I have to be able to function for the kids at home and I was no further forward at that
point I decided I just needed to know what I was taking to see, if I could get something to help at that
point, so.
EMP1004
. . . some of the ladies have got other children to look after, some of them are not getting paid so they
want to, want to get well and get back to work.
TS09
Women also reported concerns about having to seek further care and start another course of treatment
if the trial drugs did not work:
I thought it was a good idea but, I mean when I read the, what the four categories may be and that it
might not work and that I could be sick again or it could make me worse that’s what put me off?
EMP1401
However, there were reports about how smooth the process could be from both patients and staff:
All my sickness stopped and I think it was within an hour and a half later, I was home with my trial of
sickness tablets.
EMP1201
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She was feeling a bit better because she had the fluids going and then again the PI was around and she
came and consented her and then we were able to pop her on to the computer and randomise her and
then get her drugs like that. So that way worked quite well cos she felt that she was getting some
treatment before she start, kind of consented.
TS05
Preferring not to take medication
Some women reported that they were concerned about how medication would affect their
unborn baby:
I didn’t want to take the unnecessary medicines, I know they might have helped me but I just didn’t want
to harm the unborn baby.
EMP1402
On the other hand, one woman agreed to participate despite being reluctant to take drugs during
pregnancy because she reasoned that being so dehydrated could also adversely affect
her pregnancy:
I’m generally one of those people who don’t tend to take paracetamol or ibuprofen but I think when I was
worried that I was vomiting so much and so dehydrated that I was worried that I might do more damage
to my body and for the baby if I didn’t try and control it, so.
EMP1703
Another patient was also reluctant to take any medication, but her desperation to find a solution
persuaded her to participate:
I was very reluctant to take anything erm. But then I reached, obviously a point where I would have
actually taken anything I think [laughs].
EMP1702
Perceived research burden
Some staff felt that women could be discouraged by what they had to do for the trial in terms of the
information that they had to provide:
I just feel like when it’s easier for the patients it’s easier to recruit them and for them to take part but
when there’s a lot for the patients to do it sort of puts patients off a bit.
TS10
However, among those who participated, their accounts suggested that they seemed able to manage
the burden of completing trial questionnaires:
I could do the forms but I realise I was much slower and I was trying to read, you know, every word and
you know I did manage to do the forms . . . it was struggle but it was not terrible.
EMP1702
Some staff observed that patients were appreciative that they would be monitored and able to access
care more quickly than in the normal pathway:
. . . just someone to listen to your symptoms, and that was, that was really helpful for her.
TS03
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. . . she could ring us and say I’m really not feeling well so we could organise her to go in to MAC so
I think she found that quite nice that she didn’t have to ring them herself because sometimes they are
reluctant to bring people in?
TS03
Trial staff roles (theme 3)
Because of the various care pathways that women could take, and their infrequency in presenting,
research staff worked hard to catch women by ringing or visiting units within maternity, obstetrics and
gynaecology (O&G) regularly to check and remind staff:
So I try and catch them as soon as I can because if you leave it later then there’s the risk that they might
have already been given some medication . . . And if I went down and there was somebody on the ward to
come I would just sort of keep popping up and down and like I say try and catch them as soon as they
come in.
TS01
Apart from tracking, catching, screening and recruiting women, it was often necessary for research
staff to work at liaising with their clinical colleagues, especially between maternity and gynaecology:
. . . because we had to work so hard to try and get any recruits, most of the research time was spent
trying to find the women and liaising with the clinical staff about the eligibility log and reminding people.
TS16
Confidence and morale
The amount of paperwork, together with the slower than expected recruitment into the trial, had an
impact on the confidence of research staff in carrying out trial processes to the standards required in a
CTIMP. Accounts from staff on the delegation log indicated that they could be reluctant to take on the
task of recruiting a patient because the process involved felt onerous:
. . . it sounds awful but you kind of dread actually recruiting someone because you know it’s so
complicated, you know, it is really hard all the information you need to remember.
TS08
Failure to recruit was because of a number of administrative hurdles and in the early stages was a
source of frustration:
And we had given our first recruit the medication orally because she asked for it that way and hadn’t
realised that the first dose had to be i.v. so it was that, with that lady . . . and then there’s been some
issues with sending things over different e-mail addresses . . . We have had to call to clarify at the point of
recruitment on every single occasion.
TS02
Faced with the challenges of recruitment, enthusiasm for the EMPOWER trial waned. However,
successfully recruiting new participants encouraged staff to press on:
. . . we’ve found, you know women, we were kind of getting a little bit, that we keep on looking and we
can’t find women that are fitting the criteria but having the recent two recruits has been a real boost.
TS06
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Morale was also boosted when comparisons were made with other trial sites through the regular
updates provided by NCTU, and PIs reassured research staff that they were not alone:
. . . they feel better that it’s not just our site that isn’t doing as well. I mean they know that, you know,
it’s a national thing it’s not just one particular site doing, not doing as well.
TS14
When staff encountered an AE, their morale was affected; however, when they saw participants
benefiting from the care provided, they were motivated to carry on:
. . . the midwives have been on a shift where women have taken part it feels like they’ve got an
enthusiasm for the study they can see, you know, these women kind of felt better in the short term.
We know it might just be the fluids, we don’t know what really drug that we give them but it’s kind
of a positive feeling which kind of helped, you know, remind the staff that it’s a good study.
TS06
Recruitment and trial processes
Recruiting vulnerable women suffering from severe NVP was frequently reported as challenging:
I would even say that like we’ve done studies on labour ward where you’re speaking to ladies in labour
and sometimes that’s been easier than trying to speak to a lady who’s puking her guts up on the, on the
assessment unit.
TS10
Trial staff were dependent on their clinical colleagues to assist, but they reported difficulties because
of the amount of paperwork involved during recruitment that required them to be present. This made
recruitment out of hours virtually impossible:
. . . it’s a little bit more time consuming that clinical staff aren’t able to fit that in. If it’s just a short period
of time it’s not quite so bad and they will accommodate but this is a little bit more involved really I think.
TS04
. . . it’s always been really difficult to recruit patients out of hours when you’re relying on your medical
teams unless it’s really straightforward and obviously there’s a lot of paperwork that goes along with
EMPOWER recruitment isn’t there.
TS10
Staff also reported that data collection during the course of the trial could be demanding:
All the paper work you need to give, all the forms you need to fill out, you have to make sure the patients
know, you know, when to fill it in and you know, you’ve got to call the patient, well if they’re discharged at
12 hours, they’re clearly fine at 48 hours, at you know 4 days, 10 days etc.
TS08
However, staff accounts indicated that good teamwork mitigated against the demands of the trial
processes. Less confident staff reported that they felt supported by their colleagues:
But before I’d done those two I was a bit like if we get one can someone come with me so we can kind of
go through it together.
TS03
DOI: 10.3310/hta25630 Health Technology Assessment 2021 Vol. 25 No. 63
Copyright © 2021 Robson et al. This work was produced by Robson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
57
Principal investigators in the trial valued their research midwives or nurses, especially if they did most
of the liaising with fellow clinicians and co-ordinated the work of the trial:
I think the main staff on MAU they were aware of the study and I think I must give credit to [name 1]
who was like the team leader and the co-ordinator there. So she used to liaise with [name 2] who was the
research midwife and [name 3]. So [name 2] and [name 3] also co-ordinated closely with [name 1] and all
the consultants too were aware of the study.
TS22
Patient counselling and staff empathy
There were reports describing how staff counselling about the risks involved in participating in the
trial, particularly reassurance about patient care during and after the trial, was critical in the
recruitment process:
. . . sometimes they worry about the placebo–placebo but once you explain to them that you are actually
having the i.v. fluids they’re not leaving you with, you know, absolutely nothing and if it doesn’t work if
you’re feeling unwell we can take you off straight away, they do feel more reassured.
TS08
The following observations from one of the PIs summarises the importance of staff counselling and
care, not just from research staff but from clinical staff managing women at the point of admission:
. . . if, when a women came in with nausea and vomiting, the admitting midwife had a positive word to
say for the study in ways, not just of course through the study, but other ways in which the woman would
feel assured she was going to be taken care of, that makes it much easier for the recruiting team to come
on board and make that, make that case effectively for taking part.
TS18
However, while providing information about the trial, convincing patients that rehydration with i.v.
fluids was a form of treatment in itself could prove difficult.
At the same time, staff also expressed empathy for the women whom they were trying to recruit onto
the trial, such as for the long wait that women had to endure for treatment:
I do sometimes feel that the women have a rough deal if you like, because they go to the GP and then
they come to the hospital and it’s sometimes a while before they have, you know, the treatment.
TS04
If patients were given information about where they were in the queue to see a doctor, some
participants felt that this could make women more open to considering the trial:
So we want to make sure that they know that their care isn’t being held up by us as soon as the doctor
comes they’ll see them so, we just say we’re just seeing them while they’re waiting for the doctor anyway
and I think that makes them feel a bit better cos they don’t feel like we’re like sort of delaying their
treatment if you know what mean.
TS11
When approaching women, research staff had to be sensitive to how women were feeling at that point
in time, and to approach them appropriately. One patient felt that the research was more important
than the care that she was desperate to have:
But it was kind of, felt as though I’m waiting for some treatment which I’m not getting but the research
information was more important, it felt to me, cos I had got a visit about three times.
EMP1401
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On the other hand, many patients gave positive and appreciative accounts of how they were
approached, whether they accepted or declined participation:
She explained everything in detail she gave me the time I needed to process. She, basically sat there and
explained it all in all ways, in a way that I understood.
EMP1201
. . . when I spoke to them you know they said it was about my health and quality of life so they were very
good at making sure I knew what my options were to withdraw from the trial if I needed to.
EMP1703
Principal investigators mostly had complete confidence in the abilities of their research midwives/
nurses to counsel patients about their options:
They don’t have to do obviously you know sort of, in terms of consenting and everything but they’re
happy to do all the talking, and you know very objective and unbiased and stuff so.
TS15
From other feedback from interviews that described empathy for women with NVP, it appeared that
staff commitment to the trial could be compromised if they felt that participation had a negative effect
on the well-being of their patients. To illustrate this, when a SUSAR, a fetal abnormality that could
have had a link to one of the trial drugs, occurred research staff reported feeling distress and a sense
of responsibility for the patient’s treatment with the trial drugs and the subsequent termination of
the pregnancy.
Staffing levels and support
Appropriate levels of staffing were also critical to the trial; recruitment processes could have been
affected by staff being on leave:
I only work 15 hours and because we’ve been short of staff in the, in the team, really everybody, although
we’ve got about, we had about three staff until somebody just came back off long-term sick. Because
we’re so short when we’re at work we’re just mainly focusing on our own studies.
TS10
Seen from the perspective of one PI, as recruitment numbers were small, the workload for midwives or
nurses was relatively lighter than for busier trials with a large number of participants:
. . . there were few patients, even if we’d recruited to target it wasn’t many patients per centre and,
therefore, the workload for the midwives [they were] working with the women, supporting women and the
questionnaire . . .
TS16
From the perspective of other staff, however, much of their work involved keeping the EMPOWER trial
on the agendas of their colleagues. Maintaining their familiarity with trial processes that were complex
was crucial, and this was helped by the co-operation and support from fellow staff:
I’ve got lots of support though we’ve got a really good research team here and everybody kind of helps
out each other. So always kind of felt like we’ve had plenty of support during the whole thing.
TS05
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At some sites, because the AUs were so busy, research staff were involved in administering i.v. fluids
and obtaining the medication. Good relations were fostered when research staff understood the
pressures that clinical staff were under and the added burden placed on them by participation in trials:
. . . they’re working flat out and we’re constantly asking them to remember something new and something
extra and doing extra jobs. So the more you can kind of give back and take off them in terms of their
workload then yeah like you say the better the relations between the two are.
TS20
There were accounts that when trial staff did manage to recruit a woman to the trial, there was a real
sense of achievement, despite the fact that it required a lot of effort and teamwork:
The other day we did get the woman in the study there were three members of the research team that
stayed 2 hours late and one of the consultants who stayed an hour over to finally get somebody in. So we
certainly feel like we’ve gone above and beyond . . .
TS20
Conclusions
The enablers of and hurdles to recruitment in the EMPOWER trial were both trial specific and site
specific, and are summarised in Table 17.
Trial-specific factors
The issue of adherence to the RCOG guidelines12 was raised as a hurdle to recruitment, but this was
not necessarily the case if women were approached by research staff before second-line treatment
was prescribed. The problem arose when women attended AUs providing out-of-hours or 24-hour
access at times when research staff were not available. One solution was to raise awareness with
clinical teams along the care pathway so that women could be signposted to the trial. However,
publicising the trial among primary care clinicians was generally not felt to be the way forward
because of the scale of the task.
Operational difficulties at the start of the trial were to be expected, but the smooth working of the trial
was generally facilitated by good staff and professional relationships between maternity and gynaecology
departments, and with the Clinical Trials Unit. At most sites, there was a dogged determination by lead
staff to work hard at liaising with colleagues across departments and educating them about the trial and
the need to follow RCOG step-up guidelines.12 Nevertheless, the key issues for all research staff were the
unpredictability of women presenting to services and the infrequency of their presentation. These barriers
affected the efforts of research staff to recruit women in the best way possible.
The demands of the complex trial design added to the recruitment challenges faced by staff. Staff
spent most of their time finding ways and means of maintaining the profile of the trial; reminding their
colleagues about trial process requirements; and tracking, identifying and screening women. Recruiting
women was made more challenging because women with severe NVP were physically and emotionally
vulnerable; therefore, time and patience were required. Recruitment to the EMPOWER trial involved
more than just paperwork; it required high levels of empathy and patient care. Time was needed for
the patient to consider the information carefully before making an informed decision about consenting
to participate or not. Continuity of care for trial participants was provided and, where appropriate, trial
drugs were prescribed as patients requested. In this way, the issue of unblinding did not seem to be as
problematic an ethics issue as when first considered.
Women who were eligible to participate were discouraged at the thought of their condition not
improving because of the risk of receiving a double dummy. Their experience of severe NVP had an
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impact on their decision; all that they could think of was a quick, effective solution. The effort and time
required for participation, to read and understand the information, and to wait to be entered into
the trial were significant for several women. However, for altruistic reasons, there were women who
willingly participated to help others.
Site-specific factors
The care pathways that women took in seeking help for NVP were dependent on the trial site, the
catchment area and the health service provision therein. Ethnic composition, health behaviour and
antidepressant use were factors at each site. Trial sites that recruited more women were characterised
by primary care providers that tended not to prescribe trial drugs as first- or second-line antiemetics.
Sites that were unsuccessful were those that had to work hard to change the culture of prescribing
antiemetics within secondary care. Relationships with A&E departments varied across trial sites; A&E
departments in which research was not a priority was a factor. The availability and engagement of
GCP-trained staff also varied across sites. Staff confidence and morale varied depending on recruitment
rate, recruitment success, which ranged from 11% to 63% of eligible patients.
TABLE 17 Summary of enablers of and hurdles to recruitment in the EMPOWER trial
Themes Hurdles Enablers
Requirements of the EMPOWER trial
The trial question and adherence
to RCOG guidelines12
l Trial complexity
l Shift in prescribing practice
affecting eligibility
l Importance of the trial question
l Adherence to RCOG step-up
guidelines12
Organising the delivery of the
EMPOWER trial
l Difficulties of working
across departments
l Unavailability of trial unit staff
l Trial database not user-friendly
l Good working relationships
l Staff with joint clinical and
research roles
l Supportive trials unit staff
Demands of the EMPOWER trial
protocol
l Eligibility criterion of 12 hours of
first-line treatment
l Trial population of women in fragile
health state
l GCP-trained staff unavailable
l Need for double blinding
l 12-hour wait for assessment of
efficacy with possible double dummy
l Staff available to recruit women
returning after 12 hours
l Sensitivity of recruiting staff
l Sufficient pool of GCP-trained staff
l Prescriptions of trial drugs made
available to participants
Publicity and education about
the trial
l Challenges of publicising and
maintaining the profile of trial in
primary care and A&E department
l Regular publicity and training by
site research staff leading to good
co-operation from clinical and
non-clinical colleagues
Presentation of women to
maternity services
l The unpredictability of presentation
to secondary care
l The infrequency of eligible women
leading to limited staff recruitment
familiarity
l Understanding trial patient information
affected by sickness or language ability
l Patient anxiety about prolonged
sickness and hospitalisation
l Out-of-hours or 24-hour access to
specialist assessment
l Adaptation of recruitment strategies to
include inpatients
l Ongoing support for recruitment staff
l Trial flow chart for staff and patients
l Support for women to understand trial
patient information
l Staff reassurances about care,
monitoring and treatment
Trial staff roles l Confidence and morale of site
research staff affected by
low recruitment
l Clinical colleagues resistant to
support trial processes because
of workload
l Inadequate counselling by
recruitment staff
l Trial management communication
across sites to promote mutual support
l Good working relationships and liaison
with clinical colleagues
l Refresher training provided by trial
management staff
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Severe NVP is a common condition that is associated with a range of adverse maternal and infantoutcomes, and significant personal and health-care costs. Antiemetic prescribing and hospital
admissions for NVP/HG increased continuously in the UK between 1998 and 2013; by 2013, 5.2% of
pregnant women were prescribed antiemetic drugs in primary care and 2.1% were admitted.39 The
EMPOWER trial set out to determine the most clinically effective and cost-effective second-line
hospital-prescribed antiemetic therapy that should be adopted by the NHS. The trial, commissioned by
the National Institute for Health Research, followed the publication of management guidelines by the
RCOG in 201612 that recommended the use of either a dopamine receptor antagonist (metoclopramide)
or a 5-HT receptor antagonist (ondansetron or domperidone) as a second-line therapy. Three recent
reviews13–15 on treatments for NVP highlight the poor quality of the available evidence and the
heterogeneity of inclusion criteria and outcomes. Given these uncertainties, the EMPOWER trial was
designed with an internal pilot phase to test key processes of the main trial, specifically recruitment.40
However, despite the best efforts of those involved, including an extended pilot phase incorporating
revised exclusion criteria to reflect changes in clinical practice, the required number of participants was
not recruited. It was, therefore, decided, with the support of the TSC and HTA, not to progress to the
main trial. To the best of our knowledge, no RCTs of second-line antiemetic therapy have been reported
during the conduct of the EMPOWER trial and, therefore, the original question remains unanswered.
In designing the trial, we assumed a recruitment rate of 3 per 1000 pregnant women (based on
6 per 1000 women being eligible and 50% of eligible women agreeing to be randomised) based on our
experience in a prior single-centre RCT (i.e. the Hyperemesis in Pregnancy Study29) and a review
of women with severe NVP attending Newcastle upon Tyne Hospitals NHS Foundation Trust over a
6-month period. A subsequent large population-based cohort study from England, which utilised Hospital
Episode Statistics from 1997 to 2012, reported an admission rate for HG of 14.8 per 1000 pregnancies.41
Of more relevance to our trial population, 4.2 per 1000 pregnant women required two or more
admissions.41 Based on data from the seven initial pilot sites (that included 43,850 women in 2017–1842),
513 women who were assessed with severe NVP and who had been prescribed an antiemetic drug were
screened for inclusion (≈ 11 per 1000 deliveries). The overall recruitment rate of eligible women was 29%,
although this ranged from 11% to 63% at different sites. The key reason as to why recruitment was much
lower than anticipated was the high rate of ineligibility (n= 399, 78%) that, in 67% of cases, was because
of prior treatment with trial drugs, predominantly ondansetron. This was consistent across the seven sites
(accounting for 44–87% of ineligible cases) and was not substantively altered by revising the inclusion
criteria (to allow women with prior suboptimal use of the trial drug to be included). The evidence collected
from the screening logs, which was amended after the problem was identified and confirmed in interviews,
suggested that there were multiple reasons for this unexpectedly high rate of second-line antiemetic use.
We assumed that most women presenting with severe NVP would be managed by O&G services in
accordance with RCOG guidelines12 after prescription of a first-line antiemetic drug. However, we
found that nearly half of the women who were ineligible owing to prior treatment with ondansetron or
metoclopramide had been prescribed a trial drug in primary care or the A&E department. Antiemetic
prescribing by GPs is increasing; recent evidence suggests that 38–59% of women admitted to hospital
with severe NVP/HG have been prescribed antiemetic drugs by their GP.39,43 Fiaschi et al.,39 in a large
population-based cohort study from the UK between 1998 and 2014, reported that, of the 6390 (1.5%)
women admitted before 20 weeks’ gestation, 7.8% had been prescribed metoclopramide, 1.3% had been
prescribed domperidone and 0.4% had been prescribed ondansetron. In nearly 90% of cases, this was in
addition to a first-line antiemetic. The evidence collected from general practices in the north-east of
England between 2013 and 2016 (i.e. prior to the RCOG guidelines12) highlighted substantial variations
in the use of antiemetics by GPs; of relevance, 15% of antiemetics prescribed were second-line drugs
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(despite that there was a year-on-year increase in the number of women admitted with NVP).8 Of more
concern, some current primary care prescribing guidelines still differ significantly from the RCOG
recommendations.44
An increasing proportion of women with NVP were being seen by A&E services, possibly reflecting
changes in access to GPs and/or a lack of support/knowledge from GPs and community midwives on
access to care.45 A&E department guidelines for women with severe NVP vary; some refer directly to
O&G services, whereas others treat women in short-stay units, reducing treatment delays and the
need for admission.45 Antiemetic guidelines often differ from RCOG management guidelines, and there
is evidence that ondansetron and metoclopramide are preferred first-line therapies.46,47 Interviews
suggested that, having recognised the challenges, most research teams sought to increase the awareness
of the trial (and the prescribing guidelines), especially in A&E departments, where liaison was easier.
Indeed, at St George’s University Hospitals NHS Foundation Trust, where trial set-up was delayed,
it was eventually agreed that the A&E department research team should lead the trial.
Even when referral pathways operated as predicted, experienced O&G research teams faced several
recruitment challenges. Many women presented ‘out of hours’, when research staff were usually
unavailable and there were fewer GCP-accredited medical staff. This often reflected their need to
arrange child care and/or transport to hospital. However, there was also evidence that some medical
staff in O&G services did not adhere to the RCOG antiemetic guidelines, tending to prescribe a trial
drug (typically ondansetron) as the first-line treatment to resolve symptoms quickly. This was more of
a problem than we had anticipated, given that all PIs confirmed adoption of RCOG guidelines12 prior to
the start of the trial (and evidenced by submission of site guidelines). The challenges of implementing
guidelines within O&G services are widely recognised,48,49 and the modification of practitioner
prescribing practice often requires more complex interventions than the publication of guidelines
alone.50 Specific factors related to non-adherence to antiemetic prescribing may be the poor-quality
evidence of effectiveness underpinning national recommendations (quoted as level 2++, i.e. mostly
based on case–control or cohort studies12) or their recent publication with limited time to undertake
audit and feed back to monitor/improve compliance.49,51
The increased use of ondansetron to treat NVP, which is evident from the management of women
screened for participation in the EMPOWER trial, is consistent with a recent report of antiemetic
discharge prescriptions from one large UK trust between 2010 and 2015.52 Following the first
admission with HG, 45% of women were discharged with ondansetron [either alone (8.5%) or in
combination with another antiemetic (37.0%)], compared with 27.5% with metoclopramide (3.7% alone
and 23.8% in combination). The rates of ondansetron and metoclopramide prescription increased to
72.9% and 44.9%, respectively, for subsequent admissions. Prescribing practice appears to have
changed even more dramatically in the USA, with one web-based questionnaire study suggesting that
ondansetron is now the most commonly prescribed antiemetic.53 Data from both the National Birth
Defects Prevention Study and the Sloane Birth Defects Study suggest that the incidence of ondansetron
use in women with first-trimester NVP increased from < 1% in 1997–98 to 12–14% in 2013–14.54 The
increased prescribing of ondansetron, especially in combination with other antiemetic drugs, would be a
concern if the benefits do not outweigh the risks. Recent research has focused more on exploring the
harms, with little consideration given to the benefits to women and their babies. Thus, there is little
existing evidence of the benefits with which to formulate a robust assessment of the risk–benefit ratio.
Most eligible women felt very unwell: several commented on the need for a ‘quick and effective’
treatment. The protocol for the EMPOWER trial recommended rapid i.v. hydration based on limited
evidence that i.v. fluids (without antiemetics) reduced nausea.13,55 However, for some women the delay
in initiating antiemetic treatment, even for the hour required for consideration of the trial information,
and/or the chance of receiving no antiemetic treatment (i.e. the double dummy) was unacceptable.
Both recruitment barriers, inherent in the trial design as specified in the HTA programme commissioning
brief, were highlighted by the lay co-applicants and the lay members on the TSC. Considerable effort was
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made by the lay co-applicants to amend the information provided to women to ensure that it was as
brief as possible, including the use of an initial short PIS. It is noteworthy that the trial information was
commended by the REC. Most of the women who read the PIS felt that it provided a clear explanation of
why the trial was needed and the risks and benefits of participation. However, interviews highlighted that
many women rejected the PIS because they felt too unwell.
We incorporated the option of withdrawal from the IMP within the first 12 hours (if participants had
not responded to trial medication) based on advice from the lay co-applicants and feedback from the
women who had experienced NVP. Some women commented that this was reassuring. Trial staff were
empathetic to women’s social circumstances and well-being; several highlighted the ethics ‘dilemmas’
inherent in delaying antiemetic treatment and offering an unknown antiemetic (owing to double blinding)
as part of the trial, rather than one that had previously worked for the woman. The challenges of
recruiting patients into dummy-controlled trials are well recognised.56,57 A recent RCT of ursodeoxycholic
acid compared with dummy in women with intrahepatic cholestasis of pregnancy reported that 57% of
eligible women declined participation: 35% because they ‘wanted’ ursodeoxycholic acid and a further
13% because they ‘did not want to be randomly allocated’.58 Interviews with women who were approached
to participate in the EMPOWER trial confirmed two divergent themes: an explicit reluctance to take a
dummy and an altruistic desire to help increase scientific knowledge.57,59
Within O&G services there were variations in how women with severe NVP were managed. The EMPOWER
trial was designed to acknowledge the shift in care from inpatient care to day care management.12,13 A large
trial60 published just before the start of the EMPOWER trial confirmed that outpatient ambulatory care is as
effective as inpatient management. Recruiting women in busy assessment units created difficulties for
the research teams, especially given the infrequent and unpredictable presentation of the condition and
the complexity of the protocol. Interviews highlighted the need for staff at several sites to negotiate
boundaries not just between maternity and gynaecological departments, but also between research
and clinical care.61 This ‘symbolic boundary’ that typically reflects the organisational management of
professional responsibilities was negotiated differently at different sites;62 in some units these roles
were combined with positive effects and in others role differentiation was maintained throughout.
The qualitative study was unable to fully unpick some of the boundaries between research and clinical
staff, but highlighted the contribution that empathetic working relationships across these boundaries
could have on enhancing trial recruitment.
Previous systematic reviews of treatments for NVP/HG have highlighted the heterogeneity of inclusion
criteria and outcome measures.13–15 The EMPOWER trial was a pragmatic trial with simple inclusion
criteria (i.e. the managing clinician felt that there was no sustained improvement in NVP despite
taking a first-line antiemetic for at least 24 hours). Most women had been prescribed cyclizine (79%)
and/or prochlorperazine (39%) in accordance with RCOG guidelines.12 Although we opted not to use
a predefined PUQE score as an inclusion criterion, 60% of the participants had severe symptoms
(score of ≥ 13) and none had mild symptoms (score of < 7). High PUQE scores are known to be
associated with greater hospitalisation and health-care costs, as well as lower well-being and QoL.20,21
Consistent with this, recruited women had very poor QoL [with a mean baseline score on the NVPQoL
questionnaire of 186 (out of a maximum of 210)]. This is more than two standard deviations above the
mean for women in their first trimester of pregnancy.22 Both objective measures confirm that, despite
first-line antiemetic treatment, participants had severe NVP.
No core outcome set for trials on the treatment of NVP/HG was available in 2017. A subsequent review63
of outcome reporting in RCTs identified 34 distinct outcomes in 34 trials. The importance of taking
account of patients’ perspectives when designing research outcomes is widely recognised.64 We worked
with lay co-applicants and previous sufferers who prioritised treatment failure (with the need for further
treatment) as the primary outcome above several patient-reported outcomes (such as health-related QoL).65
We also sought advice on the duration of trial drug administration before treatment failure declaration,
acknowledging the balance between allowing enough time for trial drugs to have an antiemetic effect
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and the continued use of dummy in symptomatic participants. Although 12 hours was felt to be reasonable,
two out of three withdrawals occurred before 12 hours because of persistent/worsening symptoms.
A core outcome set involving 10 domains with 24 outcomes has subsequently been reported.66 Treatment
failure (as used in the EMPOWER trial) is relevant to two of the defined domains: ‘need for interventions
to manage symptoms’ (with an outcome of ‘use of additional medication’) and ‘maternal service utilisation’
(with an outcome of ‘hospital treatment’).66
No conclusions regarding the clinical effectiveness of ondansetron or metoclopramide nor the
economic analysis can be drawn from the failed pilot trial. However, a couple of clinical findings are
worth highlighting. Treatment failure was reported in a higher proportion of participants than expected
(50%). However, those who completed the questionnaires reported improvements in symptom severity
and QoL over time (including women in the double-dummy group). Consistent with high treatment
failure, almost one-third of participants were readmitted with NVP within 10 days, and two women
went on to request TOP. The findings are consistent with the 28% and 38% readmission rates reported
by Fiaschi et al.41 and Morris et al.,67 respectively. Previous studies of ondansetron and metoclopramide
have consistently documented improvements in mean symptom scores over 24–48 hours but none has
reported the need for additional antiemetic treatment during the study period.16–18,27,28 Abas et al.18
reported that 14% of women randomised to ondansetron and 18% randomised to metoclopramide
required open-label antiemetics after 24 hours of trial drug, although the duration of follow-up was
not stated. The rates of TOP for NVP in the absence of fetal anomaly are poorly reported, and the
factors associated with the decision are complex. Mazzotta et al.4 reported that 16% of women
considered TOP for NVP, and 3% reported terminating a pregnancy because of NVP. More recent
studies have reported TOP rates of 8–9%.68,69 Fejzo et al.69 reported that women with HG who took
ondansetron had a lower rate of TOP than those who did not take ondansetron (2.5% and 8.7%,
respectively). The EMPOWER trial results suggest that no second-line antiemetic treatment is effective
in all women with NVP/HG and that short-term symptom scores do not reflect the true personal and
health-care costs of the condition.
The safety profile of antiemetic drugs used in pregnancy is critical. Assessing maternal drug-related AEs
is made more complex because of the frequency of pregnancy-related symptoms, especially involving
the gastrointestinal tract. For this reason, we opted to use the National Institutes of Health CTCAE26
and recorded a change in AE grade following initiation of trial drugs. Research teams reported that the
criteria were easy to use but experience in pregnancy is still very limited; we could identify only one prior
pregnancy-related study that has used these criteria, and that was conducted in women with gestational
trophoblastic neoplasia.45 Although one participant withdrew because of perceived side effects of the trial
drugs, overall the limited evidence from the EMPOWER trial suggests that trial drugs were well tolerated.
Of particular concern to pregnant women is the risk of fetal AEs, notably congenital malformations.
Several women who were interviewed expressed concerns about the effects of trial drugs on their
unborn baby. Prior to commencing the EMPOWER trial, the available evidence suggested that
metoclopramide was not associated with any adverse fetal outcomes.70,71 Less information was
available about the safety of ondansetron in pregnancy, but a systematic review published in 201672
concluded that the risk of malformations appeared to be low. During the conduct of the EMPOWER
trial, three large studies from the USA were reported.54,73,74 Parker et al.54 analysed data from two
case–control studies and reported a modest increase in the risk of cleft palate [odds ratio (OR) 1.6,
95% CI 1.1 to 2.3] in the National Birth Defects Prevention Study (1997–2011) but not in the Sloane
Birth Defects Study (1997–2014). Huybrechts et al.73 conducted a cohort study nested in the nationwide
Medicaid Analytic eXtract (2000–13) and found no increase in the adjusted relative risk (aRR) of congenital
malformations overall, but an increased risk of oral clefts (aRR 1.24, 95% CI 1.03 to 1.48). Zambelli-Weiner
et al.74 conducted a nested case–control study using the Truven Marketscan data (2000–14) and reported
an increased risk of cardiac defects (OR 1.52, 95% CI 1.35 to 1.70) but not orofacial clefts. Based on the
available evidence, and immediately after the decision was made not to progress the EMPOWER trial
beyond the internal pilot phase, the EMA issued a signal of birth defects (specifically orofacial clefts)
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
66
following first-trimester exposure to ondansetron.75 The EMA recommended that ondansetron should
not be used during the first trimester of pregnancy.75 In response to the EMA’s signal, the UKTIS
advised that patients must be adequately counselled regarding the benefits of ondansetron together
with the small increase in risk of orofacial cleft that may exist (quantified as an excess absolute risk of
3 per 10,000 pregnancies), but that ondansetron should still be considered as an option for patients
with severe NVP in whom first-line treatments have failed.76 A very recent further study has reported
an association between ondansetron use and neonatal ventricular septal defects.77 Given these
increasing safety concerns, the failure of the EMPOWER trial to provide useful evidence to guide
practice is regrettable, especially because a key reason for failure was prescription of ondansetron.
It is widely recognised that one of the biggest threats to a RCT’s success is suboptimal recruitment,
with only 56% of multicentre RCTs funded by the HTA programme achieving their recruitment target.78
Although empirical research has helped to understand RCT recruitment issues,79 there are few effective
interventions to facilitate RCT recruitment; one such intervention is the QuinteT (qualitative research
integrated into trials) Recruitment Intervention (QRI),80 developed in 2016, and subsequently shown to
increase recruitment rates in three of four RCTs experiencing difficulties.81 Although we did not integrate
a formal two-phase QRI-type intervention into our pilot trial, we did employ most of the methodologies
designed to investigate recruitment processes (e.g. interviews with potential participants, mapping eligibility
and recruitment pathways, and scrutinising trial documentation). Having identified that prior treatment with
study drug was a key eligibility issue, there would have been benefits to extending the information collected
in screening logs and undertaking interviews with research staff earlier to more quickly understand the
contribution of care pathways. In retrospect, the ‘plan of action’,80 which focused on amending eligibility
criteria, may have been too limited and greater consideration could have been given to providing earlier
feedback about antiemetic prescribing to both clinical staff in the participating sites (in A&E departments
and O&G services) and GPs referring into sites. However, it is unknown if earlier feedback would have had
a positive and timely impact on recruitment and whether or not any impact would have been similar across
care settings.
Strengths and limitations
The major strengths of the EMPOWER trial were the inclusion of an internal pilot, with a stop–go
progression criterion based on a recruitment target, and the contribution of the public to the trial
design and delivery. Internal pilot trials are perceived to be more cost-effective than an external pilot
followed by a full trial; a recent analysis of HTA programme-funded trials reported that the proportion
with an internal pilot phase had increased to 72%.82 Given that this was a HTA-commissioned trial with
the interventions and design stipulated in the brief, we acknowledged uncertainties about recruitment
rate in the specified patient group and antiemetic failure rate. A further strength was the inclusion
of a qualitative component to explore patient understanding of recruitment and participation, which is
known to be particularly complex in trials involving pregnant women.83
The obvious limitation of the trial was the failure to achieve the recruitment target. Recruitment
problems were identified early and, with the support of the TSC and HTA, eligibility criteria were
broadened. However, inclusion of research staff in the initial qualitative interviews would have
identified the changes in care pathways and antiemetic prescribing earlier in the pilot. The value of
capturing staff experiences has been highlighted previously,79,84 and inclusion of interviews with trial
staff is recommended as part of phase 1 of the QRI.80 Despite broadening the eligibility criteria
(to allow inclusion of women who had received suboptimal treatment with study drug), we were
unable to overcome the recruitment challenges related to unforeseen changes in care pathways and
antiemetic prescribing, as well as the research culture in the trial sites.85 This led us to conclude that
the trial, as designed, was no longer feasible. Early closure minimised wastage of public funds.
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The EMPOWER trial was designed to provide guidance to health service providers on the most effectiveantiemetic drug for women with severe NVP who require secondary care. The trial incorporated an
extended internal pilot trial, involving 12 sites experienced in delivering complex obstetric trials, to
assess feasibility of recruitment. The extended pilot trial failed to achieve the revised recruitment target
and did not progress to a main trial. A higher than anticipated proportion of women were ineligible for
the trial; the main reason was prior prescription of trial medication(s) either outside O&G departments
or when women presented to O&G departments out of hours (when there was no/limited access to research
staff).This reflected a change in prescribing practice that was often inconsistent with RCOG antiemetic
guidelines, with wider use of second-line drugs, particularly ondansetron. Owing to the small sample size it
was not possible to draw meaningful conclusions from the main trial outcomes or the health economic
outcomes.The qualitative evaluation provided valuable insight into both the barriers to and the facilitators of
recruitment, which related to the requirements of the complex EMPOWER trial, the variable presentation of
women to maternity services and the research staff roles.We did not anticipate the significant changes in
ondansetron antiemetic prescribing practice, particularly outside O&G services. Had we embedded a more
formal qualitative recruitment intervention, with earlier interviews with recruiters, it is possible that we
could have identified key changes in care provision earlier, allowing a more impactful action plan, with greater
potential to increase recruitment, aimed at clinicians’ adherence to antiemetic prescribing guidelines.
Implications for clinical practice
There are no implications for clinical practice given the failure to achieve the trial objectives. We are
unable to provide improved evidence to support clinician discussions with patients about the best
choice of second-line antiemetic for NVP, other than to highlight that treatment failure appears to be
common and consideration should be given to ongoing support and follow-up to identify early those
women who fail to respond to prescribed drug(s). The study also underscores the need for effective
implementation strategies to embed guidelines into clinical practice, especially when care is
multiprofessional and involves complex care pathways.86
Recommendations for future research
1. There remains a lack of clear evidence of the clinical effectiveness and cost-effectiveness of treatment
strategies in women with NVP who fail to achieve symptom improvement with first-line antiemetic
drugs. The HTA programme should revisit this topic, especially given the recent safety concerns
about the most widely used second-line antiemetic (ondansetron).
2. More research is required to understand the barriers to recruitment of complex RCTs involving
pregnant women, especially when the condition and/or the care pathway result, in many women
presenting out of hours. Understanding the impact of wider integration of clinical and research roles
would be valuable. In addition, future trials should include resources to enable staff to be available
out of hours with a mobile pager or mobile telephone, as well as a 24-hour trials helpline, to help
overcome some of the difficulties reported by the EMPOWER trial staff.
3. Future trials of antiemetic drugs for NVP should acknowledge that short-term measurement of
symptom scores provides limited information on clinical effectiveness; treatment failures (which
result in the greatest impact on women and health-care services) frequently occur > 48 hours after
treatment initiation. Incorporation of agreed core outcomes for HG research is vital. Furthermore,
self-completion questionnaire burden is a problem in this population and alternative data collection
methods should be considered.
4. Future RCTs in which there is uncertainty around recruitment rates should incorporate an integrated
recruitment intervention, such as the QRI, into the pilot phase (or into a stand-alone pilot trial).
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Appendix 1 Pregnancy Unique
Quantification of Emesis questionnaire
Thinking about the last 24 hours, please rate how you have been by putting a tick in the relevant box.
Pregnancy Unique Quantification of Emesis score
1. In the last 24 hours how long
have you felt nauseated or sick to
your stomach?
Not at all (1) 1 hour or less (2) 2–3 hours (3) 4–6 hours (4) More than
6 hours (5)
2. In the last 24 hours have you
vomited or thrown up?
7 or more
times (5)
5–6 times (4) 3–4 times (3) 1–2 times (2) I did not
throw up (1)
3. In the last 24 hours how many
times have you had retching or
dry heaves without bringing
anything up?
No time (1) 1–2 times (2) 3–4 times (3) 5–6 times (4) 7 times
or more (5)
Total score______________
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Appendix 2 Nausea and vomiting in
pregnancy, quality-of-life questionnaire
This questionnaire has 30 questions and it has been designed to find out how you have been feelingduring the last week. You will be asked about your symptoms related to your nausea and vomiting
in pregnancy, how you have been affected in doing activities and how your mood has been. Please
complete all of the questions and select only one response for each question.












































































6. How often in the past week have you had difficulty or you have been limited or it has taken you extra effort to perform





























































10. How often in the past week have you had difficulty maintaining your normal social activities with family, friends,
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14. How often as result of your nausea and vomiting in pregnancy, in the past week have you had to rely on your partner to

























































































































































24, How often in the past week have you felt that you have accomplished less than you would like as a result of your nausea















25. How often have you cut down on the amount of time you spent at work or other activities in the past week as result of
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Appendix 3 Edinburgh Postnatal
Depression Scale questionnaire
The Edinburgh Postnatal Depression Scale questionnaire has been reproduced with permission fromCox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the 10-item
Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987;150:782–6.
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Appendix 4 Maternity Social Support Scale
The Maternity Social Support Scale has been reproduced with permission from Webster J, Linnane JW,Dibley LM, Hinson JK, Starrenburg SE, Roberts JA. Measuring social support in pregnancy: can it be
simple and meaningful? Birth 2001;27:97–101.
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Appendix 5 Health-care utilisation
questionnaire
HEALTH CARE UTILISATION QUESTIONNAIRE  
Version 2.0 dated 20/03/2019 




Health Care Utilisation Questionnaire – this can be completed via telephone interview 
or you can complete the questionnaire yourself and return to the EMPOWER trial office 
in the reply paid envelope.   
 
Please complete this questionnaire with details of your use of medical treatments and 
primary care over the last 10 days.   
 





Q1. In the last 10 days have you attended an A&E/casualty department but were not 
admitted overnight? 
 
Yes     If ‘Yes’ go to Q1B. 
 No                   If ‘No’ go to Q2. 
 
Q1B. Approximately how many times in total did you attend the A&E/casualty department 
in the last 10 days?   
Enter number of times attended the A&E/casualty department     
 
 
Q2.  In the last 10 days, have you had any face to face consultations with a health care 
professional at their practice? 
 
Yes     If ‘Yes’ go to Q2B. 
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 No                   If ‘No’ go to Q3. 
 
Q2B. if yes, please indicate what health care professional provided this face to face 
consultation at their practice and approximately how many consultations in total you  have had 
in the last 10 days. 
 
 
Health Care Professional        Yes    No    Number of Consultations 
GP 
Nurse (e.g. district/specialist nurse etc) 
 
Other health professional 
 
 











Q3.  In the last 10 days, have you had any face to face consultations with a health 
care professional at your home? 
 
Yes     If ‘Yes’ go to Q3B. 
 No                   If ‘No’ go to Q4. 
APPENDIX 5
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Q3B. if yes, please indicate what health care professional provided this face to face
consultation at your home and approximately how many consultations in total  have you had 
in the last 10 days.  
Health Care Professional     Yes    No    Number of Consultations
GP
Nurse (e.g. district/specialist nurse etc.) 
Other health professional




Q4. In the last 10 days have you had any telephone consultations with a health care
professional?
Yes If ‘Yes’ go to Q4B.
No If ‘No’ go to Q5.
Q4B. If yes, please indicate what health care professional provided this telephone 
consultation and approximately how many telephone consultations in total have you had in
the last 10 days.  
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Health Care Professional     Yes    No    Number of Consultations
GP
Nurse (e.g. district/specialist nurse etc)
Other health professional




Q5. In the last 10 days have you paid for any private health care and/or personal
care? 
Yes If ‘Yes’ go to Q5B and then move onto Section 3.
No If ‘No’ go to section.
Q5B. What type of health care you have paid for in the last 10 days and what was the cost of
this health care to you.
What heath care have you paid for?   What was the cost of this health care? 
1.___________________________ . p 
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Section 3: Work Affected by illness
Please answer the following questions regarding your current employment status and the 
effect your ill health has on your employment status (if any).
Q6. What is your current employment status? 
Full Employment Part-time Employment
Long term Sick leave from Full 
Employment (off work for more than 4 
consecutive weeks)
Long terms Sick leave from Part-time 
Employment (off work for more than 4 
consecutive weeks)
Student Caring for someone 
Housework          Unemployed, actively seeking work 
Unemployed, not actively seeking 
work 
Other Please provided details:
_______________________________
Q7. How many days (if any) have you been unable to work or carry out usual 
activities over the last 10 days? 
Total number of days: 
Thank you for taking the time to complete this questionnaire.
Date of Questionnaire Completion: __ __ / __ __ / __ __
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WILLINGNESS TO PAY QUESTIONNAIRE 
Version 1.0 dated 12/03/2018 
EMPOWER: EMesis in Pregnancy - Ondansetron With
mEtoclopRamide
Valuing the benefits of improving symptoms of moderate to severe nausea and 
vomiting in pregnancy
During pregnancy, some women experience Nausea and Vomiting. Women with 
mild symptoms are usually able to look after themselves at home without too much
difficulty. Women with more severe Nausea and Vomiting can become dehydrated, 
unable to do the things they would usually do and often need a doctor at hospital to
prescribe them medicines to help manage their symptoms. Also, moderate to severe
Nausea and Vomiting in Pregnancy can cause lots of other problems for sufferers.
For example, it can mean that women need to organise someone to help look after 
their other children or they may lose income because they are too ill to work. There 
may also be impacts on partners or other family members e.g. if they have to take
time off work to help look after other children. 
We are interested in your views about moderate to severe Nausea and Vomiting in 
Pregnancy. We would like to know your opinion on how valuable it would be to
improve symptoms of Nausea and Vomiting in Pregnancy. The questions that follow 
will help us better understand the importance of effective treatment to pregnant
women suffering from severe Nausea and Vomiting.
The information you provide will be treated as STRICTLY CONFIDENTIAL. Anything
that we publish regarding this survey will not include your name or any details about
you personally that could be used to identify you.
If you have any questions regarding this questionnaire please contact:
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Please tick ( ) the appropriate boxes and answer the more detailed questions where relevant. 
In order for us to understand more about the symptoms you have experienced 
recently in your pregnancy, we would like you to think about the different aspects of
your life that have been affected when you have had symptoms of Nausea and   
Vomiting in your Pregnancy.
Q1. From the list below choose those aspects that have TYPICALLY
AFFECTED YOU RECENTLY. 
(Please tick all that apply)
Severe nausea
(e.g. Unable to keep down any food and fluids)
Severe vomiting
(e.g. Unable to keep down any food and fluids)
Moderate nausea
(e.g. Able to keep down some food and fluids)
Moderate vomiting
(e.g. Able to keep down some food and fluids
Feeling down
Feeling tired/lethargic
Difficulty doing activities of daily life
Negative effect on family life
Reduced ability to work
Difficulty taking part in social activities
Other symptoms or activities affected
(please, specify) …….…………………………..
…………………………………
In the next part of this questionnaire, we will be using monetary values as a way to
measure how important reducing symptom severity of Nausea and Vomiting in
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Pregnancy is to you. This information helps us to understand the effect that Nausea 
and Vomiting in Pregnancy has had on your life in monetary terms. We would like to 
know what monetary value you would place on improved symptom severity.
We would like to know the maximum amount you would be willing to spend as a 
one-off lumpsum payment to experience improved symptom severity for a 10 week  
duration. When you answer this question, you can assume that this 10 week period
of improved symptoms covers the period of really intense symptoms in your pregnancy.
Improvement in symptoms varies across women, but it could mean the 
following:
1. you are able to drink enough to not become dehydrated
2. you will be able to eat and hold down more food than you are at present 
3. you are vomiting no more than twice daily and there may even be days
where you do not vomit 
4. you are able to get out of bed and take care of yourself at home 
5. your nausea is less severe 
The maximum amount you are willing to spend to improve your symptoms for 
10 weeks compared with other things you might spent your money on also gives 
us an indication of the value that you place on improving symptoms.
You will not be asked to pay anything towards your health care; we simply want to
know the monetary value that women place on a 10 week duration of improved 
symptoms of Nausea and Vomiting in Pregnancy.
Q2. We would like you to imagine a hypothetical scenario.
Think about how bad the nausea and vomiting was when you entered the 
EMPOWER study.  Imagine that you are 5 to 10 weeks pregnant and suffering  
the same symptoms of nausea and vomiting as when you entered the 
EMPOWER study. Imagine that your hospital consultant offered you 
medication that will improve your symptoms for a 10 week duration covering 
the period of really intense symptoms in your pregnancy. 
Would you be willing to pay a one-off sum of money to have improved
symptom severity from Nausea and Vomiting in Pregnancy for a 10 week 
duration? (Please tick one box)
Yes <Go to Q3> No <GO to Q6>
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Q.3 We would like to know the maximum amount you are willing to spend, as a 
one-off payment, to have improved symptom severity from nausea and 
vomiting for a 10 week duration. 
For each of the amounts shown below, please place a tick only if you are sure 
you would be willing to pay the amount stated to have improved symptom 
severity over a 10 week duration. Stop ticking when you have reached your
maximum willing to pay.
(For example if you were willing to pay up to £750 you would tick £20, £100, £200, £500, and £750)
Amount I would definitely be prepared 














More than £8,000 Go to Q.4
Q4. Referring back to your answer in Q3, please state the maximum amount  
you would be willing to pay to have improved symptom severity from nausea 
and vomiting for a 10 week duration.
(For example, if you ticked £750 but not £1,000, then please state the highest amount you would be
willing to pay between £750 and £1,000)
Maximum you are willing to pay £ 
On the following scale of 1 to 5, please state how difficult or easy it was to
provide the value above (the maximum one-off amount you would be willing to
pay). 
Please circle one number only
Extremely Easy Extremely Difficult
1 2 3 4 5 
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Q5. When answering how much you were willing to pay to have improved 
symptom severity from nausea and vomiting for a 10 week duration, what 
was/were the most important factors you were considering when thinking of 
your maximum willingness to pay? 
 
 (Please tick all boxes that apply) 
Personal income/savings  
Other financial commitments  
Unpleasantness of symptoms  
Impact of symptoms on family life  
Impact of symptoms on ability to work  








Q6. If you answered No in Question 2 - Please state the reasons you are not 
prepared to pay to have improved symptom severity, from nausea and vomiting for a 
10 week duration.  
 
       (please tick all boxes that apply) 
I do not place any value on improved symptom severity 
over a 10 week duration 
 
I believe that healthcare should be free   
Lack of budget  
Other reason (please specify below)   
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Q7. Please select the category that best describes your current employment 
status
Your current employment status (Please tick one box for you and 
one box for your partner
(if applicable))
Yourself Your partner 
In full or part-time employment/Maternity 
leave 
Looking after home and family full time
Unemployed
Short term sick 
(absence as lasting 
less than 28 calendar
days) 
Was the absence 
from work related to
your pregnancy?
Yes No 
Long term sick 
(absence as lasting 
28 or more calendar
days) or disabled





Retired from paid work altogether
Other (please, specify) 
…….…………… …….……………
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Q8. Could you please provide an estimate of your annual household income  
from all sources (before tax and including your partner/spouse)? (Please 
appropriate box). This information is needed to account for earning ability on 
the willingness-to-pay value provided earlier (it will not be used for any other 
purpose).







£45,001 and greater 
Q9: Do you have access to private health insurance?
(Please tick one box)
No
Yes 
Q10. Are there any comments that you would like to make about how Nausea 





Thank you for taking the time to complete
this questionnaire 
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Appendix 7 Interview guide
EMPOWER – telephone/e-mail interview topic guide – qualitative substudy.
Preamble:
1. Special thanks to participants for agreeing to take part in the research. Explain that one of the aims
of the study is to understand better how participants experience the process of taking part in the
trial. (For those not taking part, this includes understanding better why they decided not to take
part at all.)
2. Make the point that they do not have to answer all questions.
3. Interviewer introduces self, outlines the substudy and explains that they will receive a summary of
the results if they would wish to have one (at the end of the study).
4. (For telephone interviews.) Explain use of the audio-recorder – the interview is being audio-
recorded so I have an accurate account of what participant has said and so the researcher doesn’t
have to take handwritten notes. Interviews will be anonymised when they are typed up prior
to analysis (i.e. their names and any other information that could identify them) are taken out.
(For e-mail interviews, explain that the full e-mail correspondence will be used as the transcript. Explain
that the e-mail interview would normally involve no more than five cycles of question response.)
5. Assure confidentiality. No information will be given to your GP without permission.
6. Ask whether they have any more questions about study?
7. Ask participant to sign their copy of the consent form. Make a note on researcher copy of consent
form that consent form has been signed.
8. Explain that the interview can be ended or postponed at any time, and that this would not affect
their care in anyway.
THEN MOVE TO MAIN QUESTION GRID – begin with the introductory questions in top left corner
of grid – follow the direction of travel from participant’s response, i.e. (i) moving from left to right
through the grid, to discuss key factors, or (ii) moving from top to bottom through the grid, to discuss
reasons for taking part/not taking part.
INTRODUCTORY
QUESTIONS Issues related to the patient
Issues related to the
recruiting staff
Issues relating to the
study design
We are interested in your
views about being invited
to take part in the
EMPOWER trial
What did you think about
when you were first asked
to take part in the trial?
Initial question: why did you/
did not you want to take part
in the study?
Initial question: did the way
in which you were invited
to part affect your
decision?
Initial question: was there
anything about the study
itself that made you want/




factors made you want to








in a trial (either themselves
or family/friend)
l Belief that it might provide
access to better care
(therapeutic misconception)
l Belief that it might provide
access to closer monitoring
of health issues
l Altruistic desire to help/
contribute to improving
care for others in the
future





outcomes at the end of
the study




l Highly motivated unit
staff, proactive
recruitment strategy
l Information sheet easy
to understand and
attractive to look at
l Consent form simple
to complete
l Burden on participant
perceived to be
manageable/reasonable
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INTRODUCTORY
QUESTIONS Issues related to the patient
Issues related to the
recruiting staff
Issues relating to the
study design
l Wanting to talk about
experiences
l Believing that they will get
specific results about
their condition






factors made you NOT







l Being distressed due
to circumstances
l Distrust e.g. of health
professionals or
research etc.
l Being incapacitated by
pregnancy symptoms
l Participant does not think
they are eligible
l Apathy about research
in general
l Not wanting to talk
about experiences
l Concern about clinical
deterioration




l Concern about additional
surveillance















l Unmotivated unit staff,
passive recruitment
strategy




l Use of jargon in
explanations is
off-putting
l Perceived as potentially
getting less care
(e.g. control groups)
l Not seen as providing
any particular benefit




then fall into a control
group where no drug
treatment would
be evident)
l No opportunity to
express a preference
FOLLOW-UP QUESTIONS (if needed)




l Difficult to recall detail
about the study
l Belief that health care
is largely a trial and
error process
l Poorly explained in
invitation to participate
l Design of study
information literature
l Manner of the staff
member attempting
to recruit patient to
the study





l Not understanding what
will happen if the patient
does not get any better
in the trial
MOP-UP QUESTIONS
Could the researchers do anything else to make it easier for people to make their decision about whether to
participant?
What is the single biggest thing that made you want/not want to take part?
Looking back on the experience now, would you make the decision? Why/why not?
Is there anything else you want to tell us about your experiences?
Close interview:
Thank you for agreeing to take part in the interview
Confirm that it is still ok for the researchers to use the interview in the analysis
Confirm arrangements for participant to send in the signed consent form
Ask if the participant would like to receive a copy of the transcript
Ask if the participant would like to receive a report on the outcomes at the end of the study
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Appendix 8 Process evaluation topic
guide for interviews with clinicians
Qualitative process evaluation
Topic guide for interviews with clinicians
Interviewer outlines the purpose of the interview, which is to identify problems of recruitment into
the trial.
Interviewer explains that the participant will receive a copy of the interview transcript and a summary
of the results if they would wish to have one:
l Explain use of the audio-recorder – the interview is being audio-recorded to provide an accurate
account of what the participant has said.
l Explain that interviews will be anonymised when they are typed up prior to analysis (i.e. names and
any other information that could identify them are taken out and replaced with pseudonyms or
anonymous identifiers).
l Assure confidentiality.
l Ask whether they have any more questions about study?
l Go through and sign consent form.
The semistructured interview approach adopted in this study focuses on encouraging the participant to
explain the issues that they feel are relevant in an order that makes most sense to them. Apart from
the introduction and conclusion, the questions listed below therefore act as an aide memoire rather
than a definitive list of questions that are asked in a particular order.
Introduction
1. Can I just ask some background questions if you don’t mind? How long have you been in your
present post?
2. Can you tell me about your experience of being involved in clinical trials?
3. What has your experience been of the set-up of the EMPOWER trial?
4. How does it compare with your previous experience of other trials?
5. Can you describe how you go about recruiting patients to this trial? (MAU, EPA unit, A&E
department, pathway.)
6. What do you see are the main difficulties of recruiting patients in this trial?
7. Are there any improvements that you feel could be made to the trial processes?
8. What is your impression of patients’ understandings of a) the different treatment arms and b)
being randomised in a trial?
9. How has the progress of the trial at your site been so far?
10. Have you had any feedback from patients about the trial?
11. Are there any particular cases/events you would like to highlight to the trial investigators?
12. Do you have anything else you would like to add?
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Appendix 9 Additional baseline
demographics

























Weight at booking (kg),
median (minimum,
maximum); n with data
74 (45, 80); 7 79 (50, 113); 7 70 (60, 81); 7 67 (55, 108); 7 73 (45, 113); 28
Highest education level, n (%)
GCSEs or equivalent 2 (25) 3 (38) 1 (11) 3 (38) 9 (27)
A level or equivalent 1 (13) 1 (13) 1 (11) 2 (25) 5 (15)
Undergraduate 2 (25) 2 (25) 2 (22) 2 (25) 8 (24)
Postgraduate 1 (13) 0 (0) 1 (11) 1 (13) 3 (9)
NVQ or equivalent 2 (25) 1 (13) 2 (22) 0 (0) 5 (15)
None of the above 0 (0) 0 (0) 1 (11) 0 (0) 1 (3)
Not stated 0 (0) 1 (13) 1 (11) 0 (0) 2 (6)
Employment, n (%)
Full time 3 (38) 2 (25) 3 (33) 4 (50) 12 (37)
Part time 1 (13) 2 (25) 2 (22) 0 (0) 5 (15)
Unemployed 4 (50) 3 (38) 3 (33) 2 (25) 12 (36)
Self-employed 0 (0) 1 (13) 1 (11) 0 (0) 2 (6)
Student 0 (0) 0 (0) 0 (0) 2 (25) 2 (6)
Marital status, n (%)
Married 3 (38) 4 (50) 2 (22) 1 (13) 10 (30)
Single 1 (13) 0 (0) 0 (0) 1 (13) 2 (6)
Civil partnership 0 (0) 0 (0) 0 (0) 2 (25) 2 (6)
Stable union 4 (50) 3 (38) 6 (67) 4 (50) 17 (52)
Not stated 0 (0) 1 (13) 1 (11) 0 (0) 2 (6)
Smoking, n (%)
Never smoked 6 (75) 6 (75) 4 (44) 7 (88) 23 (70)
Quit before pregnancy 0 (0) 1 (13) 3 (33) 0 (0) 4 (12)
Quit during/owing to
pregnancy
1 (13) 1 (13) 0 (0) 0 (0) 2 (6)
Current smoker: < 5 times
per day
0 (0) 0 (0) 1 (11) 1 (13) 2 (6)
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0 (0) 0 (0) 1 (11) 0 (0) 1 (3)
Not stated 1 (13) 0 (0) 0 (0) 0 (0) 1 (3)
Alcohol use, n (%)
Never drink 2 (25) 5 (63) 3 (33) 3 (38) 13 (39)
Quit during/owing to
pregnancy
6 (75) 3 (38) 6 (67) 5 (63) 20 (61)
Illicit drug use, n (%)
No 8 (100) 8 (100) 9 (100) 7 (88) 32 (97)
Missing/not available 0 (0) 0 (0) 0 (0) 1 (13) 1 (3)
Caring responsibilities for an adult or child, n (%)
Yes 4 (50) 5 (63) 4 (44) 2 (25) 15 (45)
No 4 (50) 2 (25) 4 (44) 6 (75) 16 (48)
Not stated 0 (0) 1 (13) 1 (11) 0 (0) 2 (6)
If yes, had help since symptoms started
Yes 4 (100) 4 (80) 3 (75) 2 (100) 13 (87)
Not stated 0 (0) 1 (20) 1 (25) 0 (0) 2 (13)
Mother suffered from HG, n (%)
Yes 0 (0) 2 (25) 1 (11) 2 (25) 5 (15)
No 4 (50) 4 (50) 5 (56) 4 (50) 17 (52)
Do not know 4 (50) 2 (25) 3 (33) 2 (25) 11 (33)
Any sister who has been pregnant, n (%)
Yes 4 (50) 1 (12.5) 3 (33) 2 (25) 10 (30)
No 2 (25) 6 (75) 1 (11) 2 (25) 11 (33)
No sister 2 (25) 1 (12.5) 3 (33) 4 (50) 10 (30)
Do not know 0 (0) 0 (0) 2 (22) 0 (0) 2 (6)
If yes, suffered from HG
Yes 2 (50) 1 (100) 1 (33) 1 (50) 5 (50)
No 1 (25) 0 (0) 2 (67) 1 (50) 4 (40)
Do not know 1 (25) 0 (0) 0 (0) 0 (0) 1 (10)
MSSS total score, median
(minimum, maximum);
n with data
29 (25, 30); 8 29 (27, 30); 7 30 (27, 30); 8 29 (25, 30); 7 29 (25, 30); 30
A level, Advanced level; GCSE, General Certificate of Secondary Education; NVQ, National Vocational Qualification.
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Appendix 10 Participant-reported
symptom scores over time























PUQE score, median (minimum, maximum); n with data
Baseline 11 (8, 15); 6 14 (10, 15); 8 13 (10, 15); 9 14 (7, 15); 7 13 (7, 15); 30
Day 2 9 (3, 13); 6 5 (3, 13); 6 7 (3, 11); 7 8 (3, 12); 5 7 (3, 13); 24
Day 5 7 (5, 8); 5 7 (3, 13); 6 7 (3, 11); 7 8 (4, 15); 4 7 (3, 15); 22
Day 10 7 (6, 9); 3 8 (3, 14); 5 5 (3, 9); 5 6 (3, 9); 2 7 (3, 14); 15
PUQE severity, n (%)
Baseline
Mild (3–6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderate (7–12) 4 (67) 3 (38) 3 (33) 2 (29) 12 (40)
Severe (≥ 13) 2 (33) 5 (63) 6 (67) 5 (71) 18 (60)
Day 2
Mild (3–6) 2 (33) 4 (67) 3 (43) 2 (40) 11 (46)
Moderate (7–12) 3 (50) 1 (17) 4 (57) 3 (60) 11 (46)
Severe (≥ 13) 1 (17) 1 (17) 0 (0) 0 (0) 2 (8)
Day 5
Mild (3–6) 2 (40) 3 (50) 2 (29) 2 (50) 9 (41)
Moderate (7–12) 3 (60) 2 (33) 5 (71) 1 (25) 11 (50)
Severe (≥ 13) 0 (0) 1 (17) 0 (0) 1 (25) 2 (9)
Day 10
Mild (3–6) 1 (33) 2 (40) 3 (60) 1 (50) 7 (47)
Moderate (7–12) 2 (67) 2 (40) 2 (40) 1 (50) 7 (47)
Severe (≥ 13) 0 (0) 1 (20) 0 (0) 0 (0) 1 (7)
VAS for nausea, median (minimum, maximum); n with data
Day 2 6 (0, 9); 6 0 (0, 8); 7 3 (0, 8); 7 5 (0, 6); 5 5 (0, 9); 25
Day 5 5 (1, 5); 5 5 (0, 9); 6 6 (0, 10); 7 4 (2, 7); 4 5 (0, 10); 22
Day 10 4 (3, 8); 3 5 (0, 7); 5 1 (0, 9); 5 2 (0, 3); 2 3 (0, 9); 15
NVPQoL questionnaire, median (minimum, maximum); n with data
Baseline 178 (165, 189); 8 186 (168, 203); 7 186 (136, 205); 8 182 (132, 206); 7 186 (132, 206); 30
Day 10 148 (88, 175); 3 160 (88, 196); 4 155 (40, 170); 5 105 (81, 128); 2 148 (40, 196); 14
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Appendix 11 Participant-reported symptoms
of depression and anxiety over time
TABLE 20 Participant-reported symptoms of depression and anxiety over time (EPDS and six-item STAI)
Scale


























Baseline 14 (4, 21); 8 17 (4, 26); 8 14 (3, 20); 9 10 (5, 17); 7 15 (3, 26); 32
Day 10 12 (11, 22); 3 14 (3, 18); 5 13 (10, 22); 5 8 (5, 11); 2 13 (3, 22); 15
STAI
Baseline 17 (9, 20); 8 15 (12, 23); 7 14 (6, 24); 9 13 (8, 19); 7 15 (6, 24); 31
Day 10 15 (13, 21); 3 16 (6, 24); 5 15 (6, 22); 6 9 (6, 12); 2 15 (6, 24); 16
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Appendix 12 Clinical indicators of
antiemetic effectiveness categorising
Pregnancy Unique Quantification of Emesis
questionnaire score as relapse or remission
TABLE 21 Clinical indicators of antiemetic effectiveness categorising PUQE score as relapse or remission
Clinical indicator
























Relapse at day 5a
Number assessable 5 (63) 6 (75) 7 (78) 4 (50) 22 (67)
No 5 (100) 6 (100) 7 (100) 4 (100) 22 (100)
Relapse at day 10b
Number assessable 3 (38) 5 (75) 5 (56) 2 (25) 15 (45)
No 3 (100) 5 (100) 5 (100) 2 (100) 15 (100)
Remission at day 10c
Number assessable 3 (38) 5 (75) 5 (56) 2 (25) 15 (45)
Yes 0 (0) 1 (20) 1 (20) 0 (0) 2 (13)
No 3 (100) 4 (80) 4 (80) 2 (100) 13 (87)
a Defined as a PUQE score of ≤ 6 at day 2 followed by an increase to > 12 at day 5. Assessable if the PUQE score is
available at the day 2 and day 5 visit.
b Defined as a PUQE score of ≤ 6 at day 2 followed by an increase to > 12 at day 10. Assessable if the PUQE score is
available at the day 2 and day 10 visit.
c Defined as a PUQE score of ≤ 6 at 48 hours with return to persistent symptoms (PUQE score of ≥ 7) at day 10.
Assessable if the PUQE score is available at the day 2 and day 10 visit.
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Appendix 13 Hurdles to and enablers of
recruitment
TABLE 22 Hurdles to recruitment
Topic Hurdles
Requirements of the clinical trial Adherence to the RCOG guidelines12
Second-line treatment adopted as normal practice
Trial question out of step with current practice and not having a
high enough profile with clinicians
The liaison between maternity and gynaecology departments
needed extra work
CTU Advice not available when required
Not available out of hours
Data entry error
Demands of a CTIMP protocol Consent process takes time
GCP-trained doctor needs to consent and prescribe
Waiting time for eligibility
12 hours to see if the IMP really does not work
Publicity and education about the trial GPs and community midwifery
A&E department staff
Clinical staff on duty and out of hours
Junior doctors have to buy in
Not all aware of the trial
Trial staff roles Lacking confidence and motivation
Recruitment and trial paperwork demanding
Databases not user-friendly
Patient counselling and empathy
Staffing levels and support
Lack of confidence and familiarity
Women presenting Out of hours
Infrequently
Not had first-line treatment or not had it for long enough
Women ineligible Had not failed first-line treatment
Had trial drugs
After amendment, had trial drugs by i.v.
On antidepressant medication or other
Language ability
Women eligible Preferring previously known drug
Declining dummy
So unwell
Cannot read and understand
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TABLE 22 Hurdles to recruitment (continued )
Topic Hurdles
A lot of information
Needing a quick, definite solution
Preferring not to take medication because of possible risk
Perceived research burden
CTU, clinical trials unit.
TABLE 23 Enablers of recruitment
Topic Enabler
Requirements of the clinical trial Adherence to the RCOG guidelines12
Trial question was seen as relevant
Good staff relations and communication
CTU Staff available and responsive
Good liaison
Demands of a CTIMP protocol Counselling takes time, recruitment less so
GCP training was facilitated
Waiting time for eligibility
12 hours to see if the IMP really does not work: was acceptable
Publicity and education about the trial GPs
A&E department staff
Clinical staff on duty and out of hours
Getting staff on board
Engaging non-clinical staff
Trial staff roles Confidence and morale
Good teamwork and support for recruitment
Patient counselling and empathy
Staffing levels and workload
Confidence and familiarity
Women presenting Out of hours
Frequently
Had first-line treatment
Women ineligible Had not failed first-line treatment
On antidepressant medication
Language ability
Women eligible Counselling about the risks of a double-blind trial
The experience of severe NVP
Reading and understanding information
Information
Want a quick, definite solution
Preferring not to take medication
Extra care and attention as research participants
CTU, clinical trials unit.
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